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Phylogenetic analysis of 11 genetic loci and results from many genotyping studies revealed signiﬁcant
genetic diversity with the pathogenic Cryptococcus gattii/Cryptococcus neoformans species complex.
Genealogical concordance, coalescence-based, and species tree approaches supported the presence of dis-
tinct and concordant lineages within the complex. Consequently, we propose to recognize the current
C. neoformans var. grubii and C. neoformans var. neoformans as separate species, and ﬁve species within
C. gattii. The type strain of C. neoformans CBS132 represents a serotype AD hybrid and is replaced. The
newly delimited species differ in aspects of pathogenicity, prevalence for patient groups, as well as
biochemical and physiological aspects, such as susceptibility to antifungals. MALDI-TOF mass spectrom-
etry readily distinguishes the newly recognized species.
 2015 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cryptococcus neoformans (Sanfelice) Vuillemin is a clinically
important basidiomycetous yeast that globally causes an estimated
1 million new infections and over 625,000 deaths annually.
Although this estimate has recently been disputed, the species
remain a main source of morbidity and mortality (Park et al.,
2009, 2014a; Warkentien and Crum-Cianﬂone, 2010). According
to the current classiﬁcation the species complex comprises two
species, namely C. neoformans and C. gattii (Vanbreuseghem &
Takashio) Kwon-Chung & Boekhout (Kwon-Chung et al., 2002;
Kwon-Chung and Varma, 2006) with serotypes A, D and AD for
the former, and B and C for the latter species. Cryptococcus neofor-
mans currently consists of two varieties: C. neoformans varietygrubii (serotype A) (Franzot et al., 1999) and C. neoformans variety
neoformans (serotype D) (Kwon-Chung, 2011). With the dual
nomenclature that was in use in fungal taxonomy until recently,
the teleomorphs (i.e., the sexual stages) were named Filobasidiella
neoformans Kwon-Chung and Filobasidiella bacillispora
Kwon-Chung (Franzot et al., 1999; Kwon-Chung, 1975, 1976,
2011; Kwon-Chung et al., 2002; Vanbreuseghem and Takashio,
1970). A detailed account on the history of our knowledge of the
species was presented by Drouhet (1997), Barnett (2010) and
Kwon-Chung et al. (2011) as well as in two books (Casadevall
and Perfect, 1998; Heitman et al., 2011). A recent review on C. gattii
infections highlighted the history, epidemiology and clinical
impact of that species and its subtypes (or species) (Chen et al.,
2014).
During the past two decades, considerable genetic heterogene-
ity has been demonstrated to occur in the C. gattii/C. neoformans
species complex by a plethora of molecular methods, such as
multi-locus enzyme typing (Brandt et al., 1993), ampliﬁed frag-
ment length polymorphism (AFLP) (Boekhout et al., 2001; Hagen
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PCR-ﬁngerprinting using M13, (GACA)4 and (GTG)5 primers
(Meyer et al., 1993, 1999; Meyer and Mitchell, 1995; Sorrell
et al., 1996; Viviani et al., 1997), random ampliﬁcation of polymor-
phic DNA (RAPD) (Aoki et al., 1999; Boekhout and Van Belkum,
1997; Meyer et al., 1999; Sorrell et al., 1996), restriction fragment
length polymorphism ﬁngerprinting based on the genes CAP10
(Raimondi et al., 2007), CAP59 (Enache-Angoulvant et al., 2007;
Raimondi et al., 2007), GEF1 (Feng et al., 2008a), PLB1 (Latouche
et al., 2003) and URA5 (Casadevall et al., 1992; Kidd et al., 2004;
Meyer et al., 2003), Fourier transform infrared-spectroscopy-
based (FTIR) phenotyping (Lemmer et al., 2004), multi-locus
microsatellite typing (Hagen et al., 2012a, 2013; Hanafy et al.,
2008; Illnait-Zaragozí et al., 2010; Karaoglu et al., 2008; Pan
et al., 2012), sequence analysis of a considerable number of genes
(Bovers et al., 2008a, 2009; Butler and Poulter, 2005; Chen et al.,
2014; Diaz et al., 2000, 2005; Fraser et al., 2005; Hagen et al.,
2012b, 2013; Katsu et al., 2004; Khayhan et al., 2013; Litvintseva
et al., 2006; Meyer et al., 2009; Ngamskulrungroj et al., 2009;
Simwami et al., 2011; Springer et al., 2014; Sugita et al., 2001;
Xu et al., 2000, 2009), as well as sequence divergences based on
whole genome analyses (Billmyre et al., 2014; D’Souza et al.,
2011; Engelthaler et al., 2014; Loftus et al., 2005; Voelz et al.,
2013). The results of these studies strongly question the currently
used two species concept in the C. gattii/C. neoformans species
complex.
In addition, considerable differences have been documented
between the C. neoformans complex on the one hand and the C. gat-
tii complex on the other. For instance, the varieties grubii and neo-
formans of C. neoformans differ from C. gattii in their electrophoretic
karyotypes (Boekhout et al., 1997; Wickes et al., 1994),
DNA-ﬁngerprints (Varma et al., 1995), intergenic spacer sequences
(IGS) of the ribosomal DNA (Diaz et al., 2000, 2005), physiological
and biochemical characteristics (Bennett et al., 1978; Cherniak and
Sundstrom, 1994; Dufait et al., 1987; Kwon-Chung et al., 1987;Table 1
Current and proposed species in the C. gattii/C. neoformans species complex.
Current species name MLST Clade/
AFLP-genotypeg
P
Cryptococcus neoformans var. grubiia Clade F, AFLP1 V
Clade G, AFLP1A/VNBi V
Clade H, AFLP1B V
Cryptococcus neoformans var. neoformansb Clade I, AFLP2 V
Cryptococcus neoformans intervariety hybrid AFLP3 V
Cryptococcus gattiic Clade D, AFLP4 V
Clade C, AFLP5 V
Clade A, AFLP6 V
Clade E, AFLP7 V
Clade B, AFLP10 V
Cryptococcus neoformans var.
neoformans  Cryptococcus gattii AFLP4/VGI hybridd
AFLP8 –
Cryptococcus neoformans var. grubii  Cryptococcus
gattii AFLP4/VGI hybride
AFLP9 –
Cryptococcus neoformans var. grubii  Cryptococcus
gattii AFLP6/VGII hybridf
AFLP11 –
a Introduced by Franzot et al. (1999) for serotype A isolates.
b Introduced by Franzot et al. (1999) for serotype D isolates.
c Introduced by Kwon-Chung et al. (2002) to raise C. neoformans var. gattii to the spe
d Described by Bovers et al. (2006).
e Described by Bovers et al. (2008b).
f Described by Aminnejad et al. (2012).
g AFLP genotyping nomenclature introduced by Boekhout et al. (2001) and Hagen et a
h PCR-ﬁngerprinting and RFLP-based genotyping nomenclature as introduced by Mey
i Introduced nomenclature of a cluster of African isolates (Litvintseva et al., 2006), th
j Trilles et al. (2014) based on URA5-RFLP.
k Springer et al. (2014) based on MLST it was named genotype VGIIIc but compared tMukamurangwa et al., 1995; Ngamskulrungroj et al., 2012a;
Polacheck and Kwon-Chung, 1980), mass spectra generated by
matrix-assisted laser desorption ionization-time of ﬂight mass
spectrometry (MALDI-TOF MS) proﬁles (Firacative et al., 2012;
Hagen et al., 2011; McTaggart et al., 2011; Posteraro et al., 2012),
susceptibility to killer toxins of C. laurentii CBS139 (Boekhout and
Scorzetti, 1997), geographic distribution and habitat (Bennett
et al., 1977; Cogliati, 2013; Hagen et al., 2012b; Kwon-Chung and
Bennett, 1984a,b; Meyer et al., 2011; Springer and Chaturvedi,
2010), antifungal susceptibility proﬁles (Chowdhary et al., 2011;
Espinel-Ingroff et al., 2012a,b, 2015; Hagen et al., 2010a, 2012a;
Iqbal et al., 2010; Lockhart et al., 2012; Pan et al., 2012), induction
of cytokines (Schoffelen et al., 2013), pathophysiology (Capilla
et al., 2006; Goulart et al., 2010; Okubo et al., 2013) and clinical
manifestations (Rozenbaum and Gonçalves, 1994; Speed and
Dunt, 1995; Ngamskulrungroj et al., 2012b).
Based on the above presented phenotypic and genotypic diver-
sity, the C. gattii/C. neoformans species complex can be divided into
seven haploid and four hybrid genotypes (Table 1) (Boekhout et al.,
2001; Bovers et al., 2008a; Hagen et al., 2010a, 2012b; Meyer et al.,
2009, 2011; Ngamskulrungroj et al., 2009). Cryptococcus neofor-
mans var. grubii is represented by genotype AFLP1/VNI and the
two minor genotypes AFLP1A/VNII (i.e., genotype VNB as described
by Litvintseva et al. (2006)) and AFLP1B/VNII (Barreto de Oliveira
et al., 2004; Boekhout et al., 2001; Bovers et al., 2008a;
Litvintseva et al., 2006; Meyer et al., 2009, 2011). Cryptococcus neo-
formans var. neoformans is represented by genotype AFLP2/VNIV,
while the hybrid between both varieties fell into genotype
AFLP3/VNIII (Boekhout et al., 2001; Li et al., 2012a; Meyer et al.,
2009, 2011; Trilles et al., 2003). It is noteworthy that the original
isolate reported by Sanfelice (1895) from peach juice in Italy which
is maintained as CBS132 turned out to be a serotype AD hybrid
(Boekhout et al., 2001; Bovers et al., 2008a; Ikeda et al., 1985,
2000; Kabasawa et al., 1991; Kwon-Chung and Varma, 2006; Li
et al., 2012a). Consequently, in the current taxonomic two speciesCR-ﬁngerprinting/RFLP-genotypeh Proposed species name
NI Cryptococcus neoformans
NII
NII
NIV Cryptococcus deneoformans
NIII Cryptococcus neoformans  Cryptococcus
deneoformans hybrid
GI Cryptococcus gattii
GIII Cryptococcus bacillisporus
GII Cryptococcus deuterogattii
GIV Cryptococcus tetragattii
GIVj/VGIIIck Cryptococcus decagattii
Cryptococcus deneoformans  Cryptococcus
gattii hybrid
Cryptococcus neoformans  Cryptococcus
gattii hybrid
Cryptococcus neoformans  Cryptococcus
deuterogattii hybrid
cies level.
l. (2010a, 2012b).
er et al. (2003).
is was later conﬁrmed to be genotype AFLP1A (Bovers et al., 2008a).
o ISHAM consensus MLST it was similar to genotype AFLP10.
18 F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48concept (Kwon-Chung and Varma, 2006) this authentic isolate of
C. neoformans represents an intervarietal hybrid. Cryptococcus gattii
can be discerned into ﬁve genotypes, with genotypes AFLP4/VGI,
AFLP6/VGII and AFLP10/VGIV corresponding with serotype B
isolates, while genotypes AFLP5/VGIII and AFLP7/VGIV represent
serotype C isolates (Fraser et al., 2005; Hagen et al., 2010a,
2012b; Meyer et al., 2003, 2009, 2011). Recently, interspecies
hybrids between C. gattii and C. neoformans were described, with
the hybrid C. neoformans var. neoformans AFLP2/VNIV  C. gattii
AFLP4/VGI (serotype BD, genotype AFLP8; Bovers et al., 2006), C.
neoformans var. grubii AFLP1/VNI  C. gattii AFLP4/VGI (serotype
AB, genotype AFLP9; Bovers et al., 2008b) and C. neoformans var.
grubii AFLP1/VNI  C. gattii AFLP6/VGII (serotype AB, genotype
AFLP11; Aminnejad et al., 2012).
The status of the various lineages in the C. gattii/C. neoformans
species complex has been debated with two emerging hypotheses,
namely (a) the two species concept as supported by Kwon-Chung
and Varma (2006) versus (b) the seven species concept as suggested
by Bovers et al. (2008a), Meyer et al. (2011) and Ngamskulrungroj
et al. (2009). Here we provide strong support for the latter hypoth-
esis by performing phylogenetic analyses of 11 genetic loci of 115
globally collected isolates. The molecular data were used to
perform gene tree analyses in a maximum likelihood (ML) and
Bayesian (B/MCMC) framework and to generate coalescent-based
species trees. We employed a combination of methods to address
the species delimitation, using gene tree estimations from
single-locus and concatenated data sets, and species tree estima-
tions, including a genealogical species recognitionmethod in which
presence of clades in the majority of single-locus genealogies is
taken as evidence that these represent distinct lineages (Dettman
et al., 2003a,b; Pringle et al., 2005). We also used the
coalescent-based general mixed Yule coalescent (GMYC) method
(Monaghan et al., 2009; Pons et al., 2006), which aims at locating
the nodes that deﬁne the transitions between intraspeciﬁc (tokoge-
netic) and interspeciﬁc relationships using branch lengths. The
method has been used successfully for fungi (Leavitt et al.,
2012a,b; Parnmen et al., 2012; Pérez-Ortega et al., 2012; Powell
et al., 2011). Additionally, we used an approach that utilizes a
species tree estimationmethod to inform species delimitation deci-
sions by a likelihood ratio test that measures the ﬁt of gene trees
within a given species tree (Carstens and Dewey, 2010). For the
clinical laboratory, rapid and reliable identiﬁcation of species is
mandatory. The seven haploid lineages could be identiﬁed by
MALDI-TOF MS which is supported by our investigations in which
reference spectra for each of the new species were challenged by
more than 400 well characterized isolates of the C. gattii/C. neofor-
mans species complex. Finally, an overview is presented of the
clinical relevance of the new species.Table 2
Alignment length, variable sites for each sampled locus; and locus-speciﬁc model of
nucleotide substitution identiﬁed using the Akaike information criterion in
jModeltest.
Locus Aligned length # of variable sites Model selected under AIC
CAP59 560 108 GTR + G
GPD1 553 156 TPM1uf + G
IGS 860 471 TIM3 + G
ITS 463 16 HKY
LAC1 456 146 TPM1uf + G2. Material and methods
2.1. Isolates and culture media
The cryptococcal isolates (Supplementary Table 1) were culti-
vated on Malt Extract Agar medium (MEA) (Oxoid, Basingstoke,
United Kingdom). Cultures were incubated for 2 days at 25 C. A
working collection was maintained on MEA slants for 48 h at
25 C and at 4 C, whereas stocks were stored at 80 C using
cryo-vials (Microbank™ system, Pro-Lab Diagnostics, Richmond
Hill, ON).PLB1 536 136 TPM2uf + G
RPB1 760 120 TIM1 + G
RPB2 645 70 TPM3 + I
SOD1 437 153 TPM2uf + G
TEF1a 716 130 TIM2 + G
URA5 639 115 TPM2 + G2.2. Genetic analyses
The mating- and serotypes of the C. neoformans isolates were
determined by using four PCRs that speciﬁcally amplify theSTE20a and STE20a alleles that belong to serotype A and D
(Barreto de Oliveira et al., 2004). For C. gattii isolates the
mating-type was determined as described by Bovers et al. (2009)
using two PCRs that speciﬁcally amplify the mating-type a and a
alleles of the STE12 gene, and serotypes were taken from Hagen
et al. (2010a) in which they were analyzed by using an agglutina-
tion method (Crypto Check kit; Iatron Labs, Tokyo, Japan).
A selection of 105 cryptococcal isolates from a previous study
(Bovers et al., 2008a) was supplemented with ten additional iso-
lates to cover all known genotypes within the species complex as
well as to have all available authentic and type strains included
(Supplementary Table 1). The 55 C. gattii and 60 C. neoformans iso-
lates were subjected to ampliﬁed fragment length polymorphism
(AFLP) ﬁngerprint analysis as previously described (Hagen et al.,
2012a), followed by phylogenetic analysis after ampliﬁcation and
sequencing of 11 nuclear loci, i.e., CAP59, GPD1, IGS, ITS, LAC1,
PLB1, RPB1, RPB2, SOD1, TEF1 and URA5, as described previously
(Bovers et al., 2008a; Hagen et al., 2012b; Meyer et al., 2009). A
1000  bootstrapped Maximum Likelihood phylogenetic analysis
was performed using MEGA v5.2 (Tamura et al., 2011) in order to
ﬁnd the most optimal substitution model, namely the Hasegawa–
Kishino–Yano model with rates among sites setting ‘gamma
distributed with invariant sites’.2.3. Gene tree estimations
Maximum likelihood (ML) analyses of single loci were per-
formed using the program RAxML v7.2.7 (Stamatakis, 2006;
Stamatakis and Ott, 2008). The software jModeltest was used to
choose the nucleotide substitution model for each single locus
(Posada, 2008). The selected models for each locus are shown in
Table 2. Bootstrapping was performed based on 2000 replicates
with random sequence additions (Felsenstein, 1985). In addition,
the concatenated data set was analyzed by using ML with the pro-
gram RAxML v7.2.7 (Stamatakis, 2006; Stamatakis and Ott, 2008)
and a Bayesian approach with the MrBayes 3.1.2 program
(Huelsenbeck and Ronquist, 2001). We conducted the concatenated
data set analyses using locus-speciﬁc partitions as shown in Table 3
and each partition was allowed to have its own parameters
(Nylander et al., 2004). No molecular clock was assumed. For the
Bayesian analysis a run with 20,000,000 generations starting with
a random tree and employing 4 simultaneous chains were exe-
cuted. Every 100th tree was saved into a ﬁle. The ﬁrst 1,000,000
generations were deleted as the ‘‘burn in’’ of the chain. The program
Are We There Yet? (AWTY) was applied to compare splits frequen-
cies in the different runs and to plot cumulative split frequencies to
ensure that stationarity was reached (Nylander et al., 2008). Of the
remaining trees a majority rule consensus tree with average branch
lengths was calculated using the sumt option of MrBayes. Posterior
Table 3
Presence and ML bootstrap support of monophyletic clades in comparison to concatenated data set.
Data set Clade
A
Placement of Clade
B (CBS11687)
Clade
C
Clade
D
Clade
E
Clade
F
Clade
G
Clade
H
Clade
I
Number of strongly supported
clades (P95% ML-BP)
Concatenated data set 100% Clade B (100%) 100% 100% 100% 100% 97% 100% 100% 15
CAP59 100% Clade B (95%) 99% 100% 98% +  + 100% 8
GPD1 100% Clade B (+) 100% 100% 100% +  99% 100% 9
IGS1 99% Clade B (+) 100% 100% 100%  + + 100% 10
LAC1 100% Clade B (95%) 95% 100% 100%  +  100% 10
RPB1 99% Clade D (+) 99% + 96% 100% 97% 95% 100% 12
RPB2 96% Clade B (99%) 100% 99% 99%   + 100% 9
SOD1 + Clade D (+) + + + + + + 100% 4
TEF1 100% Clade B (+) 99% 100% 100% +  99% 100% 9
URA5 + Clade B (+) + 97% 100% 95% + 97% 100% 9
PLB1 100% Clade B (97%) 97% 100% 100% +  98% 100% 10
ITS +  + + + a a a + 0
Percentage of single locus data sets in
which the clade is present
100% N/A 100% 100% 100% 64% 45% 82% 100% N/A
+ = Present but support below 95%,  = not present.
a Sequences of clades identical and hence clades forming one monophyletic group
F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48 19probabilities were obtained for each clade. Clades with ML boot-
strap support equal or above 70% under ML and posterior probabil-
ities P0.95 were considered as strongly supported. Phylogenetic
trees were visualized using the program FigTree (Rambaut, 2009).
2.4. General Mixed Yule Coalescent (GMYC) species delimitation
The general mixed Yule coalescent approach for species delim-
itation was implemented (Pons et al., 2006). This method aims at
detecting shifts in branching rates between intra- and interspeciﬁc
relationships. Within a likelihood framework it uses chronograms
to compare two models: (a) a null model under which the whole
sample derives from a single population obeying a coalescent pro-
cess and (b) an alternative General Mixed Yule Coalescent (GMYC)
model. The latter combines equations that separately describe
branching patterns within and among distinct lineages following
a Yule model including speciation and extinction, whereas
intraspeciﬁc relationships follow a coalescent process. A likelihood
ratio test (LRT) is used to evaluate whether the null model can be
signiﬁcantly rejected. If the GMYC model ﬁts the data signiﬁcantly
better than the null model, the threshold T allows estimating the
number of species present in the data set.
Fifty-eight sequences were selected for the GMYC and species
tree analyses. As input tree, GMYC requires a fully resolved chrono-
gram, and does not allow polytomies. Since identical sequences
potentially inﬂate the number of recognized putative species, all
identical sequences, and those who were so similar that they pro-
duced polytomies in the ML tree, were excluded. We made sure to
include all strains used for the morphological and physiological
description of the species, with the exception of CBS996 (C. neofor-
mans; too similar to WM148), CBS10079 (=WM629; C. deneofor-
mans; too similar to BD5), and B5748 (C. tetragattii; too similar to
B5742). The maximum likelihood tree obtained from the concate-
nated RAxML search was used for this analysis. A chronogram was
calculated from the maximum likelihood tree using the penalized
likelihood method as implemented in the chronopl command in
the Analyses of Phylogenetics and Evolution package (APE)
(Paradis et al., 2004; Sanderson, 2002). The GMYC method requires
a fully dichotomous chronogram and thus we used multdivtime to
convert our chronogram into a fully dichotomous chronogramwith
internal branches of length zero, where appropriate (Thorne and
Kishino, 2002). This modiﬁed chronogramwas then analyzed using
the GMYC package in SPLITS in R v2.10 (http://www.cran.r-project.
org/), by using the single and multiple threshold methods. After
optimization, we plotted the lineage through time (LTT) plot with
the threshold indicated and a chronogram that had the putativespecies indicated (Nee et al., 1992). Finally, we used the summary
command to summarize the output statistics, including the results
of the LRT and the indication of the numbers of clusters and
entities.
2.5. Estimation of shared and ﬁxed polymorphisms
In order to estimate the isolation of clades, we calculated shared
and ﬁxed polymorphisms among clades using the software SITES
(Hey and Wakeley, 1997; https://bio.cst.temple.edu/~hey/).
Calculations were performed for all pairwise comparisons of spe-
cies within each of the groups studied.
2.6. Estimation of species trees
A coalescent-based approach was applied, by using the clone
corrected 11 loci sequence data set, to test alternative hypotheses
of species delimitation, testing the current species delimitation and
the delimitation of clades E–I (Fig. 1). The program Species Tree
Estimation using Maximum Likelihood (STEM) was used following
the protocol outlined previously by Carstens and Dewey (2010) to
estimate likelihood scores of alternative species delimitation sce-
narios among species trees (Kubatko et al., 2009). A set of analyses
were performed assuming the present classiﬁcation of the two spe-
cies scenario, distinction of all nine clades as species (i.e., the nine
species scenario), clades F–H representing a single species (i.e., the
seven-species scenario), clades F + G representing one species (i.e.,
8a-species scenario), clades F + H representing one species (i.e.,
8b-species scenario), and clades G + H representing a single species
(i.e., 8c-scenario). Species tree analyses were performed with max-
imum likelihood gene trees estimated for each locus separately
using RAxML v7.2.7 (Stamatakis, 2006; Stamatakis and Ott,
2008). STEM requires fully resolved gene trees, thus polytomies
were resolved by using MULTI2DI in the APE package (Paradis
et al., 2004). Maximum likelihood scores were evaluated using
likelihood-ratio tests (LRTs) to assess statistical signiﬁcance after
correcting for multiple comparisons with a Bonferroni correction.
2.7. Phenotyping assays
Growth patterns on different carbon and nitrogen sources, vita-
min requirements, growth at different temperatures and other
growth characteristics, such as extracellular starch formation,
growth at 50% glucose medium, urease activity and staining with
Diazoneum Blue B salt (DBB) were tested according to Kurtzman
et al. (2011b).
0.0070
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B
C
A
D
E
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H
I
Fig. 1. Diversity in the C. gattii/C. neoformans species complex inferred from a concatenated data set of 11 loci. The clade letters are discussed in the text, isolates indicated in
bold were used for describing the species.
20 F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48Capsule thickness was measured using Indian ink staining of 20
randomly selected cells per isolate from 1-week-old colonies that
were cultured on Littman’s ox gall agar (BD, Franklin Lakes, NJ,
U.S.A.) at both 25 and 37 C. The capsule thickness was calculated
as the ratio between the diameters of the capsule and the cell.
Cutinase, laccase, lipase, phospholipase and protease activities
were investigated in triplicate by plate assays at 25 and 37 C.
Cutinase activity was detected, according to the method described
by Dantzig et al. (1986), with p-nitrophenyl butyrate (Sigma
Aldrich, St. Louis, MO, U.S.A.) as the substrate. The yeast isolates
were grown on acetate medium (0.5% yeast extract, 0.5% peptone,
0.5% ammonium acetate, 2.0% agar). After incubation for 10 days at
25 C, a loop of cells was transferred onto a glass slide and overlaid
with freshly prepared 0.026% p-nitrophenyl butyrate containing
0.011% Triton X-100 (Sigma Aldrich). Distinct yellow staining
was considered as a positive reading.
Lipase activity was detected in triplicate according to the meth-
ods described by Sierra (1957) and Middelhoven (1997), using
Tween 40, Tween 60 and Tween 80 as substrates. The presence
of lipase activity was indicated by a diffuse zone of crystals
immersed around the yeast colony and calculated as the ratio
between the zone of precipitation and the colony diameter.
Laccase activity was measured in triplicate on L-DOPA and nore-
pinephrine media as described before (Petter et al., 2001) at 25 and
37 C. The development of brown pigment was scored daily during
10 days, with the following scores: 0 = no melanin production;
1 = center of the colony is dull brown, colony edge has no melanin
production; 2 = colony is dull brown; 3 = center of the colony is
dark brown, colony edge is dull brown; 4 = colony is dark brown
colored; 5 = colony is black colored.Phospholipase activity was investigated in triplicate using egg
yolk plates as described by Vidotto et al. (1996). The presence of
phospholipase activity was indicated by the occurrence of a clear
zone around the yeast colonies and calculated as the ratio between
the zone of enzyme activity and the colony diameter.
Protease activity was assessed in triplicate according to the
method described by Braga et al. (1998) using agar plates contain-
ing 0.75% casein. The presence of protease activity was indicated
by the occurrence of a clear zone around the yeast colonies and cal-
culated as the ratio between zone of enzyme activity and the col-
ony diameter.
The activity of 19 pathogenicity associated enzymes was tested
by using API-ZYM (BioMerieux, Marcy l’Etoile, France) (Casal and
Linares, 1983). Isolates were cultured on MEA medium and incu-
bated for 48 h at 37 C after which the API-ZYM test was carried
out according to the instructions provided by the manufacturer.
2.8. Antifungal susceptibility testing by the broth microdilution
method
The in vitro antifungal susceptibility was determined by the
broth microdilution method for amphotericin B (Bristol Myers
Squibb, Woerden, The Netherlands), 5-ﬂuorocytosine (Valeant
Pharmaceuticals, Zoetermeer, The Netherlands), ﬂuconazole and
voriconazole (Pﬁzer Central Research, Sandwich, Kent, United
Kingdom), itraconazole (Janssen Cilag, Tilburg, The Netherlands),
posaconazole (Schering-Plough Corp., Kenilworth, NJ, U.S.A.), and
isavuconazole (Basilea Pharmaceutica, Basel, Switzerland), and
minimum inhibiting concentrations calculated according to the
recommendations of the National Committee for Clinical
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Drug-free and sterile controls were included. Paecilomyces variotii
(ATCC22319) and Candida krusei (ATCC6258, CBS573) were used
for quality control. Microtiter plates were incubated at 35 C for
72 h under aerobic conditions.
2.9. Virulence study
Virulence was studied in a murine model as described by Falk
et al. (1999) as follows. Yeastswere injected into the tail vein ofmale
albino BALB/c mice (weight, 20 ± 3 g) by administration of a single
bolus of a 0.2 ml suspension in PBS. Two inocula were used for each
cryptococcal isolate, namely 5  105 and 5  106 yeast cells per
mouse made from a 48 h old culture grown at 30 C on Sabouraud
glucose agar (SGA) (Difco, Detroit, MI, U.S.A.). The yeast concentra-
tion was determined by counting with a haemocytometer. Viable
count was measured as the number of CFU on SGA plates after
48 h of incubation. Each test group included ten mice. Virulence
was based on lethality and determined by recording the number of
dead animals in each group daily for 30 days. The virulence was
scored between values 4 (high) and 1 (low). Level 4 represented iso-
lates that killed the mice within 5 days (high inoculum) or 10 days
(low inoculum); Level 3 –within 12 days (high inoculum) or 20 days
(low inoculum); Level 2 and Level 1 represent strains that killed 50%
or 10% of the mice within 30 days, respectively.
Cryptococcus neoformans strain H99 was used as a reference. All
procedures, care and treatment of mice were in accordance with
the principles of humane treatment outlined by the Guide for the
Care and Use of Laboratory Animals of the Hebrew University,
and were approved by the Committee for Ethical Conduct in the
Care and Use of Laboratory Animals (approval number
OPRR-A01-5011).
2.10. Matrix-assisted laser desorption ionization-time of ﬂight mass
spectrometry identiﬁcation
The CBS-KNAW in-house made database contained 150 refer-
ence Main Spectra (MSPs) of representatives of all genotypic
groups of the C. gattii/C. neoformans species complex
(Supplementary Table 2). This set included 74 MSPs from 38
strains of the C. gattii complex, 31 MSPs of 17 strains of C. neofor-
mans serotype A (currently classiﬁed as variety grubii), 16 MSPs
of 9 strains of C. neoformans serotype D (currently classiﬁed as vari-
ety neoformans) and 7 MSPs of 7 hybrid strains including serotype
AD, serotype BC and serotype BD. In addition, 16 MSPs of 16 strains
of serotype AD hybrid strains grown on SGA were added. Sixty-ﬁve
strains were cultured on Sabouraud glucose agar (SGA) for 24 h at
30 C and 69 strains were grown on media that reduce capsule for-
mation, namely SGA + 0.5M NaCl. As no differences were observed
in the identiﬁcation results by using MSPs of C. gattii and C. neofor-
mans grown on both culture media, for the remainder identiﬁca-
tions SGA without salt was used. Ethanol/formic acid protein
extraction was done according to the protocol of the manufacturer
(Kolecka et al., 2013; Marklein et al., 2009). The test set of 423
Cryptococcus isolates included representatives of the C. neoformans
(n = 225) and the C. gattii complexes (n = 145), and serotype AD,
serotype AB and BD isolates (n = 53). All these isolates were previ-
ously characterized by using a combination of molecular tech-
niques, including AFLP ﬁngerprinting, multi-locus sequence
typing (MLST) and mating- and serotyping PCRs (Bovers et al.,
2006, 2008a,b, 2009; Hagen et al., 2010a, 2012a,b, 2013;
Khayhan et al., 2013; Pan et al., 2012). The isolates used to test
the MSPs present in the database were measured in duplicates
and identiﬁed using a 96-spot polished steel target plate (Bruker
Daltonics) as described before (Kolecka et al., 2013). Bacterial
Test Standard solution (Bruker Daltonics) was included as apositive control in all test series. MALDI-TOF MS identiﬁcation
results were achieved automatically as the log-score values
deﬁned as the ‘secure species identiﬁcation’ (>2.0), ‘secure genus
identiﬁcation’ (1.7–2.0) and ‘no reliable identiﬁcation’ (<1.7, NRI).
The identiﬁcation was considered correct if at least one spot from
the duplicates gave a reliable identiﬁcation with score >1.7.3. Results
3.1. AFLP and multi-gene sequence analysis
AFLP ﬁngerprinting separated the isolates in clusters that were
fully concordant with previously observed genotypic groups
(Barreto de Oliveira et al., 2004; Boekhout et al., 2001; Bovers
et al., 2006, 2008a,b; Hagen et al., 2010a, 2012a,b). The current C.
neoformans variety grubii was represented by three subclusters,
namely AFLP1/VNI (n = 25), AFLP1A/VNII/VNB (n = 7) and
AFLP1B/VNII (n = 8), whereas C. neoformans var. neoformans as
interpreted hitherto was represented by one cluster, namely
AFLP2/VNIV (n = 20). Cryptococcus gattii fell apart in ﬁve different
clusters, named AFLP4/VGI (n = 18), AFLP5/VGIII (n = 10),
AFLP6/VGII (n = 19), AFLP7/VGIV (n = 6) and AFLP10/VGIV (n = 2).
Subsequent multi-gene sequence analysis using 11 nuclear loci
resulted in a similar clustering (Figs. 2 and 3; Table 1) as observed
with the AFLP genotyping and was in agreement with previously
obtained results (Bovers et al., 2008a; Diaz et al., 2000, 2005;
Hagen et al., 2010a, 2012b; Meyer et al., 1999, 2003, 2009). When
all eleven lociwere analyzed individually, the single gene treeswere
concordant between the various loci (Supplementary Figs. 1 and 2).3.2. Gene tree estimations and species delimitations
The number of nucleotide positions and variable sites for each
locus are given in Table 2 together with optimal evolutionary mod-
els as determined using AIC. The resulting clades, their genotypic
afﬁliation and new taxonomy ranks are given in Table 1. Single
locus ML analyses revealed highly congruent tree topologies with
seven clades and one singleton: ﬁve (clades A–E, G) were strongly
supported in all single locus analyses (Table 3), one clade was pre-
sent in all but two analyses (clade H), and two clades were present
in 45% (clade G) and 64% (clade F) of the single locus analyses,
respectively. In addition, one strain (CBS11687) did cluster with
either clade C or E in the single locus analyses (data not shown).
In the concatenated analyses, the ML and Bayesian searches
revealed almost identical trees with strong support for all clades
identiﬁed in the single locus analyses (Table 3). In the combined
analysis sample CBS11687 clustered strongly supported with clade
C but with a long branch leading to it.
The coalescence-based single threshold General Mixed Yule
Coalescent (GMYC) identiﬁed eight putative species (clades A–I)
with the concatenated data set, and between six and eight in the
single locus analyses (Table 4). In the multiple threshold method,
ten putative species were found with the concatenated data set,
and between seven and eleven in the single locus analyses.
Except for the URA5 data set, single and multiple threshold analy-
ses did not reveal signiﬁcantly different likelihood values and,
hence, in those cases the simpler single threshold method was pre-
ferred. In the URA5 data set, the single threshold result was signif-
icantly better than the multiple threshold result and, consequently,
for all analyses the single threshold result was preferred.
The protocol by Carstens and Dewey (2010) was applied to gen-
erate species trees from a given set of gene trees under different
species delimitation scenarios. By using the same set of gene trees,
scenarios were compared that included a nine-species, three differ-
ent eight-species scenarios, a seven-species scenario, and the
CBS7229
RV54130
E566
WM179
CBS11232
WM176
CBS883
CBS919
CBS7748
WM276
CBS6289
CBS8273
CBS6290
48A
56A
CBS1622
CBS6992
CBS6998
CBS11687
IHEM14941W
WM161
WM726
WM728
CBS6996
CBS8755
CBS6955
CN043
384C
CBS5758
CBS6993
M27055
WM779
A47496
C16528
B5742
B5748
A1M R272
RAM2
ICB184
CBS8684
CBS10089
CBS1930
HEC11102
CBS10090
WM178
A1M F3016
A1M R409
CBS6956
CBS7750
A1M R406
A1M F2866
A1M F2932
A1M R265
A1M R269
A1M R271
CBS10511 C. deneoformans AFLP2/VNIV reference strain
CBS10513 C. deneoformans AFLP2/VNIV reference strain
WM629 C. deneoformans AFLP2/VNIV reference strain
AMC940441 C. neoformans AFLP1B/VNII reference strain
WM626 C. neoformans AFLP1B/VNII reference strain
Bt63 C. neoformans AFLP1A/VNB/VNII reference strain
CBS8710 C. neoformans AFLP1/VNI reference strain
WM148 C. neoformans AFLP1/VNI reference strain100
100
99
100
80
100
100
99
89
100
92
78
97
100
100
100
87
99
93
100
99
100
99
97
100
93
100
97
0,01
iittag.
C A
FL
P
4/
V
G
I
iittagaced.
C A
FL
P
10
/V
G
IV
suropsillicab.
C
A
FL
P
5/
V
G
III
iittagartet.
C A
FL
P
7/
V
G
IV
iittagoretued.
C
A
FL
P
6/
V
G
II
Fig. 2. Concatenated loci phylogenetic bootstrapped maximum likelihood analysis of C. gattii species complex isolates by using C. neoformans species complex isolates as an
outgroup.
22 F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48current two-species scenario, as explained under Section 2. An
information-theoretic approach that accommodates for number
of parameters strongly supported a seven-species scenario with a
Log Likelihood value of 19054.752 (Table 5) over the set of other
species delimitation scenarios (Bonferroni corrected P-values<0.001 in all cases). The current two-species classiﬁcation received
the worst likelihood scores of 30090.767 (Table 5). Thus based on
the above given considerations there is strong evidence for a seven
species concept in the C. gattii/C. neoformans species complex. See
Figs. 1–4.
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The physiological growth proﬁles by using a large diversity of
carbon and nitrogen compounds did not differ widely among the
species (for the formal taxonomy see below under Taxonomy)
and interspecies hybrids as many carbon sources were utilizedby all species (Table 6; Supplementary Fig. 3; Supplementary
Table 3). D-Galactonate was not utilized by isolates of C. deneofor-
mans and malic acid was used by most isolates of the C. gattii spe-
cies complex, and less by those from C. neoformans. Most isolates of
C. neoformans and C. deneoformans grew on propane-1,2-diol,
whereas the serotype AD hybrids, representatives of the C. gattii
Table 4
Results of species delimitation using the GMYC method for the concatenated and the single locus data sets including single and multiple thresholds.
Data set L(0) L(GMYCsingle) P Number of
putative species
L(GMYCmultiple) P Number of
putative species
Difference between single
and multiple threshold p
Concatenated data set 467.894 474.510 0.0042⁄ 8 475.101 0.0061⁄ 10 0.758NS
CAP59 237.397 240.112 0.143NS 6 240.929 0.216NS 7 0.950NS
GPD1 242.255 246.182 0.049⁄ 8 246.948 0.095NS 8 0.957NS
IGS 245.908 265.983 60.001 7 267.906 60.001 7 0.065NS
LAC1 248.466 250.969 0.171NS 8 251.705 0.166NS 7 0.689NS
RPB1 246.686 252.041 0.013⁄ 8 253.052 0.026⁄ 9 0.918NS
RPB2 244.045 249.083 0.018⁄ 7 249.739 0.044⁄ 8 0.971NS
SOD1 243.615 248.551 0.019⁄ 8 248.797 0.110NS 8 0.999NS
TEF1a 248.947 251.275 0.199NS 7 252.669 0.188NS 11 0.835NS
URA5 246.741 259.301 60.001 6 252.124 0.029⁄ 9 0.0024⁄
PLB1 240.696 242.664 0.268NS 7 243.696 0.389NS 7 0.984NS
ITS 219.457 226.953 0.002⁄ 7 224.921 0.053NS 7 0.668NS
NS = not signiﬁcant.
⁄ Signiﬁcant difference at p < 0.05.
Table 5
Likelihood scores for STEM analysis of species delimitation scenarios.
Scenario lnL k 2 (D – lnL) Bonferroni corrected P
7-species 19054.752 8 0
8a-species 20823.570 9 3537.636 <0.001
8b-species 22535.729 9 6961.954 <0.001
9-species 22536.085 10 6962.666 <0.001
8c-species 23413.632 9 8717.76 <0.001
2-species 30090.767 3 22072.03 <0.001
k = number of parameters.
24 F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48species complex and the C. gattii  C. neoformans and C. gattii  C.
deneoformans hybrids did not. With respect to the growth on
N-compounds, creatinine and L-lysine were assimilated by all iso-
lates. Creatine was not utilized by (most) isolates of C. neoformans
and C. deneoformans, but allowed growth of most isolates of C. deu-
torogattii and C. tetragattii. Ethylamine and D-proline were not uti-
lized by isolates of C. neoformans and C. deneoformans, but allowed
growth of most of the isolates of the C. gattii species complex
(Table 6, Supplementary Table 3). No growth occurred with cadav-
erine (except a few C. deneoformans and the serotype AD hybrid
isolates), glucosamine, imidazole (note that C. deuterogattii and C.
tetragattii isolates had a ring of growth at some distance from
the well), nitrate, nitrite, and D-tryptophan. All isolates of all spe-
cies utilized extracellular starch, hydrolyzed urea, showed a posi-
tive DBB staining and required vitamins for growth. Most isolates
were able to grow on 50% glucose, but (most) not on 60% glucose.
All isolates were able to grow at 25, 30, 35 and 37 C (note that iso-
late CBS5467 (C. deneoformans) and CBS919 (C. gattii) showed vari-
able growth at the latter temperature), growth was variable at8.3%
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Fig. 4. Diagram showing results of identiﬁcation of test set o40 C but absent in isolates of C. bacillisporus, and no growth
occurred at 42 C.
Although melanisation rates were quite variable, the highest
values were seen in serotype AD hybrids as all isolates had black
colored colonies after 24 h at both 25 C and 37 C, and was found
to be slower in isolates of C. neoformans, C. bacillisporus and
C. deuterogattii, whereas melanisation rates were lowest in isolates
of C. deneoformans and C. gattii (Suppl. Table 3). Isolates of
C. deuterogattii showed higher melanisation rates at 25 C on nore-
pinephrine media (Supplementary Fig. 3).
Phospholipase activity showed a variable result for almost all
species. Several isolates showed a somewhat greater phospholi-
pase activity at 25 C. Protease activity was low and variable
among the isolates of the various species.
Thickest capsules were present in isolates of C. gattii followed
by those of C. neoformans, C. deneoformans, C. bacillisporus and C.
deuterogattii (Supplementary Table 3). Isolates of the serotype AD
hybrids had the thinnest capsules and the driest colonies as well.
Cutinase activity was not observed in any species (except the
gattii  neoformans hybrid) at 25 C, but occurred at 37 C in most
isolates of C. neoformans, C. deneoformans and C. bacillisporus.
Lipase activities, tested using Tweens 40, 60 and 80 plates,
showed variable reactions among the various species. Activity with
Tween 40 was higher at 25 C than at 37 C. Strains CBS6996 (C.
bacillisporus) and isolates of C. tetragattii showed the highest
activities. No activities were seen for the following enzymes
(except for a few isolates): lipase C14, valine arylamidase, trypsin,
a-chymotrypsin, a-galactosidase, b-galactosidase, n-acetyl-b-glu-
coaminidase, a-mannosydase and a-fucosidase. Activities of44.9%
C. neoformans
C. deneoformans
C. gattii
C. bacillisporus
C. deuterogattii
C. tetragattii
C. decagattii
C. neoformans × C. deneoformans hybrid
C. neoformans × C. deneoformans hybrid
with parental match  only
C. deneoformans × C. gattii hybrid
C. neoformans × C. gattii hybrid
f all species and interspecies hybrids by MALDI-TOF MS.
Table 6
Salient phenotypic data for species in the C. gattii/C. neoformans species complex.
Phenotypes Species
C. neoformans C. deneoformans C. gattii C. bacillisporus C. deuterogattii C. tetragattii C. decagattii
DL-Lactate + + + +  (+) + +
Propane-1,2-diol + v /w /w  /w +
D-Galactonate + ()  + v + () + ?
Malic acid v v + v + + ?
Inulin v  (+) + () + + + +
Ethylamine  (w)  (w) + + + + +
D-Proline   + + v + +
Creatine   v v v v 
CGB medium   + + + + +
Esterase C4 + + w w w w w
ECV amphotericin B (lg/ml)a 0.5d/1 1 0.5 1 0.5e/1 1 1f
ECV 5-ﬂuorocytosine (lg/ml)a 8d/16 16 4 4 16 4 4f
ECV ﬂuconazole (lg/ml)b 8d/16 16 8 8 8e/32 16 16f
ECV itraconazole (lg/ml)b 0.25d/0.5 0.5 0.5 0.5 0.5 1 1f
ECV posaconazole (lg/ml)b 0.25 0.25 0.5 0.5 0.5 0.5 0.5f
ECV voriconazole (lg/ml)b 0.25 0.12 0.5 0.25 0.25 0.25 0.25f
ECV isavuconazole (lg/ml)c 0.06/0.12d 0.06 0.25 0.25 0.25 0.25 0.25f
Phenotypic scoring: + = growth;  = no growth; v = variable growth; w = weak growth; value between brackets indicate deviation from main growth pattern.
a Epidemiological cut-off values (ECVs) as determined by Espinel-Ingroff et al., 2012a.
b Espinel-Ingroff et al., 2012b.
c Espinel-Ingroff et al., 2015.
d ECV for C. neoformans genotype AFLP1/VNI.
e ECV for C. deuterogattii genotype AFLP6A/VGIIa.
f Due to the low number of C. decagattii isolates, the general ECVs for the C. gattii species complex, or when applicable those for C. tetragattii were applied (C. decagattii
cannot be discerned from C. tetragattii by low-discriminatory ﬁngerprint techniques).
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phatase, a-glucosidase and b-glucosidase were highest in strains
of the C. neoformans complex (Supplementary Fig. 3;
Supplementary Table 3).
3.4. Antifungal susceptibility testing
All tested isolates were susceptible for amphotericin B and
had MICs equal or lower than the deﬁned epidemiological
cut-off values (ECVs) of 0.5 and 1 lg/ml (Table 6,
Supplementary Table 3; Espinel-Ingroff et al., 2012a). For
5-ﬂuorocytosine, MICs were available for isolates of the C. gattii
species complex and were observed to be lower, equal and one
dilution-step higher than the deﬁned ECV of 4 lg/ml for C. tetra-
gattii, and below the ECV of 16 lg/ml for C. deutrogattii. When
the general C. gattii species complex ECV for 5-ﬂuorocytosine
was considered (16 lg/ml) than all isolates had MICs lower than
the ECV of 16 lg/ml (Table 6, Supplementary Table 3;
Espinel-Ingroff et al., 2012a).
Cryptococcus neoformans isolates had MICs for ﬂuconazole equal
or lower than the ECV of 8 lg/ml, none of the C. deneoformans iso-
lates had a MIC for ﬂuconazole that were higher than the deﬁned
ECV of 16 lg/ml for non-typed C. neoformans species complex iso-
lates (Table 6, Supplementary Table 3; Espinel-Ingroff et al.,
2012b). Similarly, none of the intervariety hybrid C.
neoformans  C. deneoformans and C. gattii species complex isolates
had ﬂuconazole MICs that were higher than the proposed ECVs
(Supplementary Table 3; Espinel-Ingroff et al., 2012b). MICs for
itraconazole and posaconazole were for all tested isolates equal
or below the proposed ECVs (Table 6, Supplementary Table 3;
Espinel-Ingroff et al., 2012b). Nearly all isolates had MICs for
voriconazole that were equal or below the proposed ECV, however,
some C. deuterogattii isolates had MICs that were 1 lg/ml and were
higher than the proposed ECV of 0.25 lg/ml (Table 6,
Supplementary Table 3; Espinel-Ingroff et al., 2012b). All tested
C. neoformans isolates, except one, had MICs that were below the
recently proposed ECV of 0.12 lg/ml for isavuconazole. For C. dene-
oformans and the intervariety C. neoformans  C. deneoformans iso-
lates no ECV was established, but the tested isolates had MICs thatwere equal or below the ECV of C. neoformans (Table 6,
Supplementary Table 3; Espinel-Ingroff et al., 2015). The proposed
isavuconazole ECV of 0.25 lg/ml was established for isolates that
belongs to the C. gattii species complex. In general the MICs
observed were below this ECV but some C. gattii and C. deuterogattii
had MICs that were higher (Table 6, Supplementary Table 3;
Espinel-Ingroff et al., 2015).3.5. Virulence assays
Most of the isolates tested for virulence showed low to moder-
ate virulence using both high and low inocula. Three isolates
showed high virulence, namely CBS5467 of C. deneoformans (geno-
type AFLP2) frommilk of a mastitic cow), a C. neoformans  C. dene-
oformans hybrid isolate NY-J40 (genotype AFLP3) from an AIDS
patient, and CBS6993 of C. bacillisporus (genotype AFLP5) isolated
from a non-AIDS patient.3.6. Identiﬁcation of genotypic groups by MALDI-TOF MS
By using the CBS-KNAW in-house database together with the
Bruker BDAL database (3995 MSPs, v3.1.2.0) all 423 isolates
(100%) of the C. gattii/C. neoformans species complex were identi-
ﬁed by MALDI-TOF MS at the species level (Fig. 4). By using dupli-
cates, 322 isolates (76.1%) were identiﬁed with scores >2.0 on both
spots, 98 strains (23.2%) had scores >2.0 only on one spot from
duplicates, and three strains (0.7%) gained scores (1.7–2.0) on both
spots. Four attempts were needed to accomplish measurements of
all strains enrolled for testing by MALDI-TOF MS.
The identiﬁcations generated by MALDI-TOF MS were further
evaluated for the correct genus and species recognition based on
the previous molecular and genetic analyses as well as for the con-
cordance with one of the seven species and the intervariety and
interspecies hybrids. Overall, a correct identiﬁcation at the species
and AFLP genotype level was obtained for 415 (98.1%) out of 423
isolates. Straightforward identiﬁcation and AFLP genotype match
gained all isolates of C. bacillisporus, C. deuterogattii, C. tetragattii
and C. decagattii and the C. neoformans  C. gattii and
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Fig. 5. Re-analysis of available MLST-data from isolates that fell into putative C. bacillisporus and C. decagattii clusters.
26 F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48C. deneoformans  C. gattii hybrids. Fifty-eight from the 59 C. gattii
isolates were correctly identiﬁed on both spots, one isolate (4–
308), however, gained a C. gattii species complex identiﬁcation
and matched with C. gattii on one spot and C. deuterogattii on the
other. The recognition of C. deneoformans was correct for 34 of
the 35 (97.1%) isolates, and one isolate (CBS7814) gained anatypical hybrid match with serotype AD hybrids and a ‘No Peaks
Found’-score. A correct recognition of the serotype AD hybrids
resulted for 26 (52%) of 50 strains, whereas the remaining 24 iso-
lates gained either a ‘parent/parent’ or a ‘hybrid/parent’ match
from duplicates. For 13 isolates a serotype AD match was detected
on one spot and C. neoformans on the second. For 4 isolates a
F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48 27correct hybrid match was found on one spot and C. neoformans on
the second. Six isolates matched with C. neoformans on both spots
and one strain with C. deneoformans on both spots.4. Discussion
The taxonomy of the Cryptococcus gattii/C. neoformans species
complex has been debated since the extensive genetic and biochem-
ical diversity within the complex became clear (Kwon-Chung and
Varma, 2006). At the 6th and 8th International Conferences on
Cryptococcus and Cryptococcosis (ICCC6 and 8) held in 2005 in
Boston and 2011 in Charleston, lively debates on the matter were
held (Coenjaerts, 2006; Del Poeta and Casadevall, 2012; Del Poeta
et al., 2005). Before the ICCC6 meeting was held, a nomenclature
paper settled the taxonomic position of C. gattii (Kwon-Chung
et al., 2002), and this decision was readily adopted by the research
and clinical communities. However, the discussion on the taxo-
nomic status of the genotypic groups as recognized in both C. neofor-
mans and C. gattii continued (Bovers et al., 2008a; Hagen et al.,
2010a, 2012b; Kwon-Chung and Varma, 2006; Meyer et al., 2009,
2011; Ngamskulrungroj et al., 2009). Importantly, fully concordant
results (Table 1) were obtained by many molecular taxonomic
investigations irrespectivewhether theywerebasedonenzyme typ-
ing (Brandt et al., 1993), DNA fragment analysis (e.g., AFLP, RFLP,
PCR-ﬁngerprinting), sequence analysis of a number of genes
(Bovers et al., 2008a; Byrnes et al., 2010, 2011; Findley et al., 2009;
Fraser et al., 2005; Hagen et al., 2012b, 2013; Litvintseva and
Mitchell, 2012; Litvintseva et al., 2006; Meyer et al., 2011;
Ngamskulrungroj et al., 2009; Springer et al., 2014; Sugita et al.,
2001), and comparative genomics data (Billmyre et al., 2014;
Cuomo and Litvintseva, 2014; D’Souza et al., 2011; Engelthaler
et al., 2014; Fisher, 2014; Heitman, 2014; Meyer et al., 2011; Sun
et al., 2013; Voelz et al., 2013).4.1. Taxonomic and phylogenetic concepts
Here, we used genealogical (Taylor et al., 2000) and
coalescent-based (Fujita et al., 2012) species delimitation methods
based on phylogenetic trees of 11 genomic loci. Both genealogical
and coalescent-based analyses demonstrated that the current two
species classiﬁcation does not reﬂect the phylogenetic relationships
within the C. gattii/C. neoformans species complex, but that more
distinct lineages exist within the group. All methods strongly sup-
ported seven clades (labeled A–I in Fig. 1; Tables 3–5) to be distinct
lineages, i.e., species. We consider the congruence of different
methods that rely on independent analysis, i.e., monophyly and
support in single locus analyses in genealogical approaches, differ-
ences in branch lengths in GMYC, and likelihood values of species
trees, as a strong indication that those seven lineages represent spe-
cies. The results for clades F and G differed between the analyses
and we have chosen here a conservative approach and consider
them genotypes within C. neoformans, since we agree with
Carstens et al. (2013) that it is better to fail to delimit species than
to falsely delimit entities that do not represent distinct evolution-
ary lineages and therefore a conservative approach was chosen that
potentially underestimates the diversity in the group. Clade H was
supported as a distinct lineage, while the genealogical and species
tree approaches did not support them as distinct, the GMYCmethod
identiﬁed them as distinct putative species. However, the GMYC
has been shown to overestimate the number of species in speciﬁc
cases, although it hasmostly been shown to be a robust tool for spe-
cies delimitation (Fujisawa and Barraclough, 2013; Hamilton et al.,
2014; Reid and Carstens, 2012; Talavera et al., 2013). Furthermore,
isolates of genotypes AFLP1A/VNB/VNII (clade G) and AFLP1/VNI
(clade F) of C. neoformans (serotype A) were found to recombine(Litvintseva et al., 2003, 2006) thus giving further evidence to con-
sider them as a panmictic group.
Many species concepts are in use in biology, but in mycology the
phenetic, biological and phylogenetic species concepts have been
most widely used. When reviewing the available literature on the
taxonomy of the C. gattii/C. neoformans species complex it occurred
to us that most published data are in agreement, or at least not in
conﬂict, with the recognition of the current main genotypic groups
as species. Recently, the species concept as applied in a number of
eukaryotic pathogens, including Cryptococcus spp., was discussed
using the concept of Predominant Clonal Evolution (PCE)
(Tibayrenc and Ayala, 2014). Hallmarks of PCE are highly signiﬁcant
linkage disequilibrium and near-clading (‘clonal near-clades’). The
latter was described as ‘stable phylogenetic clustering clouded by
occasional recombination’ and according to these authors both
occur in Cryptococcus spp. (Tibayrenc and Ayala, 2014). As far as
we know no recombination has been detected between the major
genotypic groups in the C. gattii/C. neoformans species complex,
although this may be blurred by the occurrence of interspecies
diploid or aneuploid hybrids that are heterozygous and genetically
not very stable. Reversals to (near) haploid stages cannot be ruled
out and selection of one of the orthologs from the hybrid progeny
may be interpreted as recombination. In our opinion the presence
of these hybrids strongly suggests post-zygotic isolation mecha-
nisms that hinder regular meiosis (see also below). We do not favor
PCE in the case of the C. gattii/C. neoformans species complex as the
species are characterized by stable multigene data and other geno-
typic methods such as PCR-ﬁngerprinting and AFLP, they can be
identiﬁed phenotypically by differences in the proteome
(MALDI-TOF MS), and they show differences in disease symptoms
and susceptibility to antifungals. Moreover, emerging whole gen-
ome analyses support their genetic separation as well. The concept
of PCE seems valid at the population level within the species that
we recognize as recombination may occur (e.g., in C. neoformans, C.
deuterogattii), and clonal expansionsmay result in the relative dom-
inance of some subgenotypes and amating-types, e.g., in C. neofor-
mans, C. bacillisporus and C. deuterogattii.
Kwon-Chung and Varma (2006) strongly favored a two species
concept in the complex. This was based on the notion that many
phenotypic differences have been documented to occur between
isolates of the C. neoformans and C. gattii species complexes. We
do not dispute this, but, on the contrary, novel technologies, such
as MALDI-TOF MS, distinguished all major genotypes (Firacative
et al., 2012; Hagen et al., 2011; Posteraro et al., 2012; current
study). All molecular taxonomic studies separated the major geno-
types (see above) in the complex, but in some studies alleles of ser-
otype AD hybrid isolates clustered with either serotype A or D
isolates (see e.g., Diaz et al., 2005 and the discussion on this topic
in Kwon-Chung and Varma, 2006). These observations are, how-
ever, a consequence of the diploid or aneuploid nature of hybrid
genomes that may have two alleles for all or many genes, one rep-
resenting the serotype A allele and the other the serotype D allele.
In case these alleles have not been cloned before sequencing,
which was the case in the Diaz et al. (2005) study, an erratic phy-
logenetic pattern may occur. One may interpret this as a lack of
concordance between genotypes and serotypes as was done by
Kwon-Chung and Varma (2006), but in our opinion this is a conse-
quence of the hybrid nature of such genomes and the methodolog-
ical limitations of studies when genes are directly sequenced from
PCR-amplicons.
4.2. Comparative genomics and sequence divergence
The amount of sequence divergence between single copy ortho-
logs in the genomes of strain H99 (serotype A, genotype
AFLP1/VNI) and JEC21 (serotype D, genotype AFLP2/VNIV) was on
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gattii WM276 (serotype B, genotype AFLP4/VGI) this was 11%
(Janbon et al., 2014). In another study the divergence between
the genomes of B3501A (serotype D, genotype AFLP2/VNIV) and
C. gattii WM276 (serotype B, genotype AFLP4/VGI) was found to
be 13% and between the genomes of B3501A and C. gattii
A1M-R265 this was 14.5% (serotype B, AFLP6A/VGIIa) (D’Souza
et al., 2011). The genomes of the two serotype B strains WM276
and A1M-R265 (D’Souza et al., 2011), as well as those of C. neofor-
mans var. neoformans JEC21 (serotype D, genotype AFLP2/VNIV)
and C. neoformans var. grubii H99 (serotype A, genotype
AFLP1/VNI) (Janbon et al., 2014) were found to be largely
co-linear, whereas between the genomes of the two serotype B
strains and both the serotype A and serotype D strains many ﬁxed
and unﬁxed rearrangements were observed (D’Souza et al., 2011;
Janbon et al., 2014; Sun and Xu, 2009). Phylogenomic analysis of
5171 single gene orthologs indicated that the time since diver-
gence of serotype A versus both serotype B strains was found to
be 34 million years (myr) ago, whereas divergence between
genotype AFLP4/VGI and AFLP6/VGII was 7.6% corresponding to
12.4 myr (D’Souza et al., 2011). Divergence between serotype A
(H99, genotype AFLP1/VNI) and serotype D (JEC21/B3501, geno-
type AFLP2/VNIV) was estimated 20 myr (time as indicated in
Fig. 2 in D’Souza et al., 2011). Another study suggested that the
C. neoformans and C. gattii complexes separated 80 myr, but with
a broad range of 16–160 myr. A population genomics study of
the C. gattii species complex, focusing on North American outbreak
isolates, studied the genomes of 118 isolates and found that the
four major genotypes, i.e., AFLP4/VGI, AFLP5/VGIII, AFLP6/VGII,
and AFLP7/VGIV, clustered separately with more than 500,000
SNPs occurring between AFLP6/VGII and the other genotypes
(Engelthaler et al., 2014). Patterns of intron evolution also sepa-
rated the C. gattii and C. neoformans species complexes (Croll and
McDonald, 2012). Genomes of AFLP4/VGI, AFLP5/VGIII and
AFLP6/VGII, AFLP1/VNI and AFLP2/VNIV showed distinct patterns
of intron presence/absence. Nineteen isolates of AFLP6/VGII had
the same intron pattern, as did two isolates of AFLP4/VGI, and
two isolates of AFLP2/VNIV (Croll and McDonald, 2012).
Multigene phylogenetic analyses yielded somewhat different
divergence times (Meyer et al., 2011; Ngamskulrungroj et al.,
2009; Xu et al., 2000). Concatenated sequences of the mtLrRNA,
ITS, and URA5 and LAC genes (Xu et al., 2000) and the ACT1, IDE1,
PLB1, and URA5 genes (Meyer et al., 2011) suggested that the C.
neoformans and the C. gattii species complexes separated 37 or
49 myr based on the two data sets, respectively; the two current
varieties in C. neoformans separated 18.5 and 24.5 myr, respec-
tively, the four included lineages within C. gattii became distinct
between 2.6–9.5 and 8.5–12.5 myr, and the AFLP1/VNI and
AFLP1A/VNB/VNII lineages of serotype A separated 4.7 myr.
Introgressions have been observed to occur between some of the
genotypic groups in the C. gattii/C. neoformans that we propose to
represent species. For instance, a 14-gene region of approximately
40 kb in size was found to be horizontally transferred from a strain
with serotype A background to one with a serotype D background
(Kavanaugh et al., 2006). In our opinion these comparative gene
phylogenies and genomics data strongly suggest that the current
major genotypes of the C. gattii/C. neoformans species complex
should be interpreted as species.
4.3. Phenotyping
Because a considerable number of phenotypic and genotypic
differences has been observed to occur between the C. neoformans
and C. gattii species complexes, we wondered whether they agree
with the recognized genotypes and if they differ in phenotypic
aspects. Therefore, we investigated whether isolates belonging tothe various species differed with respect to virulence related fac-
tors, such as capsule thickness, rate of melanin formation, lipase,
phospholipase and protease activity, as well as nutritional require-
ments, and antifungal susceptibility to clinically used antifungal
compounds. Several phenotypic data separated the C. neoformans
species complex from the C. gattii species complex, e.g., the CGB
reaction, some stronger enzyme activities, growth on ethylamine,
and D-proline, and to some extent malic acid. Furthermore, C. dene-
oformans (AFLP2/VNIV) was able to grow on D-galactose, which
was absent in the remainder. Because the natural niche of C. neo-
formans and C. gattii species complexes seem to be on trees and
tree-related habitats (Chowdhary et al., 2011, 2012a,b, 2013;
Colom et al., 2012; Hagen and Boekhout, 2010; Kidd et al., 2007;
Lazéra et al., 1998; Springer and Chaturvedi, 2010), we tested a
number of enzymes, such as cutinase, laccase and lipase that play
a role in the degradation of plant material. When compared to an
older study (Schmeding et al., 1984) in which the nutritional
requirements of carbon and nitrogen compounds of 79 strains
was analyzed a number of differences became apparent. For
instance, most if not all strains in our study utilized citric acid, cre-
atinine, erythritol, inulin, sorbose and succinic acid. In agreement
with other authors (Dufait et al., 1987; Kwon-Chung and Varma,
2006) most strains of the C. gattii species complex were able to uti-
lize D-proline and all were CGB positive. Furthermore, they were
also able to grow with ethylamine. Contrary to most other species,
strains of C. deneoformans (genotypic group AFLP2/VNIV) did not
utilize glycerol. Ngamskulrungroj et al. (2012a) observed that iso-
lates of the C. gattii species complex were able to grow with
D-alanine, L-phenylalanine and L-tryptophane, but not isolates of
the C. neoformans species complex. Unlike C. neoformans, isolates
of C. deneoformans (genotypic group AFLP2/VNIV) grew poorly with
L-phenylalanine and L-tryptophan (Ngamskulrungroj et al., 2012a).
Contrary to L-tryptophan we observed that D-tryptophan could not
be utilized by any member of the C. gattii/C. neoformans species
complex. Our data suggest differences in the activities of a number
of extracellular enzymes between members of the C. gattii and C.
neoformans species complexes. Unfortunately limited data on these
enzymes have been published, and in that study no distinction was
made between genotypes or species (Vidotto et al., 2006).4.4. Genetic crosses
Detailed analyses of genetic crosses among and between iso-
lates of species candidate groups, including the F1 and F2 genera-
tions are needed to observe reproductive barriers to approximate
biological species concept. Unfortunately, most of the mating
experiments done in the C. gattii/C. neoformans species complex
do not fulﬁll these requirements. In many cases just a few tester
strains, belonging to e.g., C. deneoformans (previously C. neoformans
var. neoformans, AFLP2/VNIV, e.g., JEC20, JEC21) or C. bacillisporus
(previously C. gattii AFLP5/VGIII, e.g., B4546, NIH312) have been
used to induce a mating response. In almost all cases the observa-
tions stopped when hyphae and clamp connection and/or basidia
were observed. Detailed genetic analyses of the F1 have usually
not been made, and as far as we know none of the F2 generation.
This hampers interpretation of results from mating experiments
for taxonomic purposes. This is particularly true as many sexual
reproduction strategies occur in the complex (see e.g., Nielsen
and Heitman, 2007), including hybridization. The presence of
hybrid isolates in the complex, such as the serotype AD, BD and
AB hybrids (Aminnejad et al., 2012; Boekhout et al., 2001; Bovers
et al., 2006, 2008b; Cogliati et al., 2006, 2011; Lengeler et al.,
2001; Li et al., 2012a; Lin et al., 2007, 2008; Litvintseva et al.,
2007; Hagen et al., 2010a, 2012b; Meyer et al., 2009, 2011;
Ngamskulrungroj et al., 2009; Sun and Xu, 2007; Vogan and Xu,
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vide an argument that the parental isolates of these hybrids are
genetically isolated and represent species. This is strongly sup-
ported by recent observations in which Bateson–Dobzjansky–Mul
ler incompatibility affected the viability of basidiospores that
resulted from crosses between isolates of serotype A and serotype
D (Vogan and Xu, 2014). If compared to crosses among serotype A
isolates and among serotype D isolates, the hybrid crosses yielded
low numbers of fertile offspring suggesting that the putative par-
ental groups are post-zygotically separated (Kwon-Chung and
Varma, 2006; Lengeler et al., 2001; Lin et al., 2007), and are unable
to go through normal meiosis. Kwon-Chung and Varma (2006)
analyzed crosses between strains H99 (serotype A, genotype
AFLP1/VNI) and JEC20 (serotype D, genotype AFLP2/VNIV) and
between CBS6289 (serotype B, genotype AFLP4/VGI) and B3502
(serotype D, genotype AFLP2/VNIV). The 20 offspring isolates of
the serotype AD cross were largely diploid or aneuploid, i.e., 70%,
with complex serotypes, mating-types and mixed serotype AD, A
or D allelic patterns of 5 genes. Three haploid isolates agreed with
JEC20, and three were thought to be recombinants as they had the
serotype A allele of CNLAC and serotype D alleles of CAP59 and
URA5. However, as the diploid or aneuploid genomes are highly
dynamic one cannot rule out that the observed recombinants are
not the result of a meiosis, but of post-zygotic chromosome/gene
sorting. The same isolates were also crossed by Cogliati et al.
(2006) with similar results, except that no haploid recombinants
were observed. A crossing between the serotype A isolate CDC15
and serotype D isolate JEC20 showed a much shorter genome
map length and a much higher physical distance to genetic dis-
tance ratios for this cross when compared to crosses among sero-
type A or among serotype D isolates (Sun and Xu, 2007). Lin
et al. (2007) noted that serotype AD hybrids are inefﬁcient in meio-
sis and sporulation and remained in the diploid state. Serotype AD
diploid strains were found to be either sterile (70%) or self-fertile
(30%) (Lengeler et al., 2001) and thus mating incompetent.
Analysis of another serotype A  serotype D mating yielded a
hybrid F1 with AD phenotype and genotype (Tanaka et al., 2003).
These authors concluded that serotype AD isolates are diploid for
many but not for all genomic loci. Another study demonstrated
highly dynamic genomes with extensive loss of entire or partial
chromosomes in serotype AD strains (Li et al., 2012a) that resulted
in variable phenotypes, e.g., related to the serological epitopes.
Serotype AD hybrid isolates have arisen by multiple recent (0-ca.
2 myr) hybridization events (Xu et al., 2002).
A crossing between strain CBS6289 (serotype B, genotype
AFLP4/VGI) and B3502 (serotype D, genotype AFLP2/VNIV)
yielded 50% diploids or aneuploids and 50% parental D strains.
No haploid recombinants were recovered (Kwon-Chung and
Varma, 2006). This, in our opinion, indicates that these two
strains are genetically separated and the lack of recombinants
suggests a considerable genetic distance. Part of the serotype
BD diploids were phenotypically unstable in that the serotype
BD phenotype switched to the serotype D phenotype
(Kwon-Chung and Varma, 2006).
Within the C. gattii species complex crosses between strains of
AFLP5/VGIII and AFLP6/VGII were performed and compared with
crosses among AFLP6/VGII strains (Voelz et al., 2013).
Intergenotypic crosses resulted in low rates of spore germination
(<1%), low rates of successful meiosis with one crossing giving
two out of 16 progeny being haploid recombinants and the other
cross yielding diploid progeny only. Crosses among AFLP6/VGII iso-
lates yielded a higher number of viable recombinant basidiospores
(Voelz et al., 2013). Thus the results from the intergenotypic
crosses largely corroborated that they represent genetically iso-
lated cryptic species that are separated by post-zygotic isolation
barriers. Kwon-Chung et al. (1982) studied a crossing betweenATCC34874 (serotype D, genotype AFLP2/VNIV) and ATCC32609
(serotype C, genotype AFLP5/VGIII) and reported two types of
basidiospores. Progeny of one basidium seemed to represent the
serotype D parental with an 1:1 segregation of mating-types,
whereas the progeny of the second basidium studied showed an
1:1 ration of Mal+ and Mal strains. Another crossing presented
by these authors was between ATCC32269 (serotype B, genotype
AFLP4/VGI) and ATCC34874 (serotype D, genotype AFLP2/VNIV),
viability of the basidiospores was 25–30% and 27% were
self-fertile. A third crossing was between two other genotypic
groups of the C. gattii species complex. Strain ATCC32269 (serotype
B, genotype AFLP4/VGI)  strain ATCC32608 (serotype C, genotype
AFLP5/VGIII) produced 30% fertile basidiospores and 30% of them
were self-fertile. Phenotypic analysis of the offspring does not pro-
vide clues whether recombination has occurred. Unfortunately, the
ploidy of the offspring of these last three crossings was not
assessed and a detailed genetic analysis not performed. In our
opinion, it cannot be ruled out that the basidia were the result of
interspecies crossing with diploid or aneuploid basidiospores.
Similarly, all but one of the crossings between ATCC36555 and
ATCC28958 (serotype D, genotype AFLP2/VNIV) performed by
Schmeding et al. (1981) represented interspecies crossings.
Although the images of the basidia presented are somewhat difﬁ-
cult to interpret and a genetic analysis of the offspring was not
made, their presence clearly suggest that post-zygotic isolation
occurs between many genotypic groups, i.e., species.
Evidence of mitochondrial recombination was observed
between various lineages of the C. gattii species complex, notably
between genotype AFLP4/VGI and both genotype AFLP6/VGII and
genotype AFLP7/VGIV (Bovers et al., 2009). All the observed genetic
mechanisms acting within and between members of the C. gattii/C.
neoformans species complex renders this a genetically highly
dynamic evolutionary complex generating signiﬁcant genotypic
and phenotypic diversity that may provide ﬁtness advantages for
the various species and lineages under diverse environmental con-
ditions. Interspecies hybrids are not limited to fungi, but occur in
many lineages of the eukaryote tree of life, including fungi, plants
and animals (Arnason et al., 1991; Benirschkek et al., 1964;
Megersa et al., 2006; Mine et al., 2000; Weiss-Schneeweiss et al.,
2013). In a very recent study mitochondrial inheritance was stud-
ied within and between isolates belong to various genotypes [read
species] in the C. gattii species complex (Wang et al., 2015).
Interestingly, various inheritance patterns as well as recombinants
were observed. Recombinants were seen in three out of seven intra
molecular type VGIII crosses, in two of the molecular type
VGII  VGII crosses and in 3 out of molecular type VGI  VGIII
crosses, thus corroborating previous observations on the presence
of mitochondrial recombination in the C. gattii species complex
(Bovers et al., 2009). As the main mechanism of speciation in the
C. gattii/C. neoformans species complex is regulated by post zygotic
isolation mechanisms [see above] it remains to be seen how these
patterns of mitochondrial recombination play a role in the specia-
tion processes.
With the data at hand, however, we demonstrate evidence
from different analyses that the C. gattii/C. neoformans species
complex consists of more species than currently accepted, in
agreement with other groups of fungi (Crespo and Lumbsch,
2010; Hibbett and Taylor, 2013: Lumbsch and Leavitt, 2011;
Taylor et al., 2000). The seven-species concept for the C.
gattii/C. neoformans species complex, adopted here, represents
the minimal species diversity in the group and additional data
will be necessary to elucidate the taxonomic status of clades
F–H. This seven species concept is supported by the phyloge-
netic species concept and largely corroborated by available phe-
notypic data and information on post-zygotic isolation barriers
that can be interpreted as a proxy for the biological species
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phylogenetic studies will unveil other cryptic species in the
complex, e.g., in C. neoformans.
4.5. Virulence and susceptibility to antifungals
Only few studies have addressed comparative aspects of viru-
lence among all members of the C. gattii/C. neoformans species com-
plex. One study used Galleria mellonella as a model host to compare
the molecular types of C. gattii (Firacative et al., 2014). No relation-
shipswere found between themolecular types and cell size, capsule
thickness, production of melanin, and growth rate at 37 C.
Although not statistically signiﬁcant, the authors noted that isolates
of genotype AFLP4/VGI (=C. gattii sensu stricto in new taxonomy)
caused a higher proportion of death in a shorter time than strains
of genotypes AFLP5/VGIII (=C. bacillisporus in new taxonomy),
AFLP6/VGII (=C. deuterogattii in new taxonomy), and VGIV (either
C. tetragattii or C. decagattii in new taxonomy). Another study used
Drosophila as amodel host (Thompson III et al., 2014). These authors
investigated most genotypic groups in the complex [note that they
did not include genotype AFLP2/VNIV (=C. deneoformans in new tax-
onomy) nor the serotype AD hybrids] and found that genotype
AFLP5/VGIII (=C. bacillisporus in new taxonomy) was the most viru-
lent group. Growth at 30 C was also highest for isolates of this
group, but at 37 C this was genotype AFLP1/VNI (=C. neoformans
in new taxonomy). Similar to our results capsules were thickest
for C. gattii isolates, especially genotypes AFLP4/VGI (like our
results) and AFLP5/VGIII (unlike our data). These authors also
showed that at 30 C, genotype AFLP1/VNI isolates produced more
melanin than the C. gattii species complex genotypes. Similarly iso-
lates of genotype AFLP1/VNI showed better tolerance to hydrogen
peroxide. They also noted differences in susceptibility to antifun-
gals between the so-called genotypic groups (Thompson III et al.,
2009, 2014). MICs to ﬂuconazole and itraconazole were higher in
genotype AFLP6C/VGIIc (=C. deuterogattii subtype C in new taxon-
omy) than in genotypes AFLP4/VGI (=C. gattii in new taxonomy)
and AFLP6/VGII (=C. deuterogattii in new taxonomy), as well as
genotype AFLP1/VNI (=C. neoformans in new taxonomy) for ﬂucona-
zole. MICs for posaconazole were higher for genotype AFLP6C/VGIIc
than for genotype AFLP1/VNI. According to these authors survival of
Drosophilawas related tomolecular type (=species) or subtype (=in-
traspecies). Virulence in immunocompetent mice of a strain of C.
gattii (genotype AFLP4/VGI) that was isolated from a goat in Spain
was compared with that of a C. deneoformans (serotype D) and a
C. bacillisporus (serotype C) isolate (Torres-Rodríguez et al., 2003).
In all cases mortality was low (2%), but the highest rates of positive
cultures from tissuewere from C. gattii, followed by C. deneoformans
and C. bacillisporus. Finally, it was observed that C. neoformans
(genotype AFLP1/VNI) grew faster in the brain and C. deuterogattii
(cited as C. gattii genotype AFLP6/VGII) in the lungs of C57BL/6
and BALB/c mice (Ngamskulrungroj et al., 2012b). Moreover,
growth in blood by C. deuterogattiiwas slower than that of C. neofor-
mans. In brief, these and our studies suggest differences in virulence
and pathogenicity of, at least, part of the new species in the C.
gattii/C. neoformans species complex. It is, however, likely that sig-
niﬁcant strain-based differences exist in virulence within the spe-
cies as was demonstrated using tail-vein inoculation experiments
in mice and macrophages using many globally collected isolates
of C. deuterogattii (Hagen et al., 2013).
The ﬁrst practice guidelines for the treatment of cryptococcal
infectionswere established by Saag et al. (2000) who described sev-
eral treatment strategies for different patient groups. These include
monotherapy with ﬂuconazole for immunocompetent individuals
and combined amphotericin B and 5-ﬂuorocytosine induction ther-
apy followed by a prolonged ﬂuconazole consolidation therapy
(Saag et al., 2000). The outcomes of two large epidemiologicalstudies initiated by the French Cryptococcosis Study Group pleaded
for updated guidelines (Dromer et al., 2007, 2008). A decade after
the ﬁrst consensus practice guidelines for the treatment of crypto-
coccosis, a thorough update was provided by Perfect et al. (2010).
These updated practice guidelines include an induction therapy
with amphotericin B and 5-ﬂuorocytosine with different doses for
speciﬁc groups (e.g., patient groups, clinical presentation, C. gattii
versus C. neoformans species complexes), followed by a period of
consolidation with ﬂuconazole. Resistance has been reported for
these antifungals, especially for ﬂuconazole when used as
monotherapy (Pan et al., 2012; Sar et al., 2004; Van Wyk et al.,
2014). A review on cases of ﬂuconazole resistant clinical isolates
showed that this might be due to monotherapy but that heterore-
sistance can be a potential alternative route (Cheong and
McCormack, 2013; Sionov et al., 2009). Hence the necessity to per-
form routine testing of MICs for clinical cryptococcal isolates
remains.
4.6. Identiﬁcation of species
Rapid and reliable identiﬁcation of clinically important fungi is
highly important. Fortunately, a number of recently developed
approaches make this feasible for the species of the C. gattii/C. neo-
formans species complex. One such technique is MALDI-TOF MS
that has been successfully applied to identify and separate closely
related pathogenic yeasts (Cendejas-Bueno et al., 2012; Firacative
et al., 2012; Kolecka et al., 2013). Correct identiﬁcation of C. gattii
and C. neoformans and their genotypes by MALDI-TOF MS was
reported (Firacative et al., 2012; Hagen et al., 2011; McTaggart
et al., 2011; Posteraro et al., 2012). These results are largely con-
ﬁrmed by our results for which a test set of 425 well characterized
isolates was used. Major errors, i.e., as incorrect genus identiﬁca-
tion, were not observed and minor errors, viz. misidentiﬁcation
at the species level, were found occasionally between hybrid
strains. Use of media known to impact capsule development, i.e.,
SGA versus SGA + 0.5M NaCl, did not inﬂuence the identiﬁcation
results. Thus, MALDI-TOF MS is an excellent method to identify
members of the C. gattii/C. neoformans species complex reliably
at the species level. PCR-RFLP analysis of the CAP1 and GEF1 genes
also allowed identiﬁcation of all species and their mating-types in
the C. gattii/C. neoformans species complex (Feng et al., 2008a).
Hyperbranched rolling circle ampliﬁcation (HRCA) using
species-speciﬁc (referred to as molecular types by the authors)
padlock probes based on the PLB1 gene allowed discrimination of
all species (Trilles et al., 2014). Other studies separated C. neofor-
mans, C. deneoformans and the C. gattii species complex (Feng
et al., 2013; Kaocharoen et al., 2008) by singleplex PCR analysis
of the STR1 gene and a HRCA targeting the ITS, respectively.
Older studies using the Luminex xMAP technology with genotype
and species speciﬁc primers based on the IGS1 region were able
to identify all the newly recognized species, but we have to keep
in mind that isolates of C. tetragattii and C. decagattii were not
available at that time (Bovers et al., 2007; Diaz and Fell, 2005b)
and need further testing. To some extent this method successfully
identiﬁed Cryptococcus cells directly from infected CSF (Bovers
et al., 2007).
4.7. The position of CBS132 as type strain and naming the species
After we recognize the species, a further point of concern is how
to name them? Strain CBS132 is assumed to represent an original
isolate made by Sanfelice (1895) and was selected as the type
strain of C. neoformans (dried material in Herbarium BPI802707,
ex-type culture CBS132) which is the conserved type species of
the genus Cryptococcus (Fonseca et al., 2011; Kwon-Chung, 2011;
McNeil et al., 2006). This strain was send to CBS-KNAW by
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inal isolate made by Sanfelice. However, in the 3rd edition of the
reference work ‘The Yeasts – A taxonomic study’ (Phaff and Fell,
1970) the authors were not fully convinced that this strain origi-
nated from Sanfelice as they wrote ‘One strain, received by the
CBS in 1935 from Giordano in Italy, was assumed [italics by present
authors] by Lodder and Kreger-van Rij (1952) to be the original
strain of Sanfelice and was chosen by them as the type strain’.
Various attempts to assess the serotype of isolate CBS132 yielded
different results. Serological studies, including a dot enzyme assay,
multi-locus enzyme typing, AFLP analysis, and PCR and dot blot
analysis of mating-type pheromones showed it to be a serotype
AD hybrid (Belay et al., 1996; Boekhout et al., 2001; Brandt et al.,
1993; Cogliati et al., 2001; Ikeda et al., 1996, 2000; Kabasawa
et al., 1991). Kwon-Chung et al. (1978) reported that it had sero-
type D as did Dromer et al. (1993) who found an immunoﬂuores-
cence pattern consistent with serotype D by using a monoclonal
antibody against capsular polysaccharides. The latter authors
noted the discrepancy with the reported serotype AD status. In
contrast, Lengeler et al. (2001) reported serotype A for this strain
using the CryptoCheck serotyping kit from Iatron Laboratories.
The same authors found that by using PCR analysis several
mating-type locus linked genes gave either a serotype A + D, an
A, or a D-speciﬁc pattern, ﬂow cytometry yielded a diploid genome
size, and the isolate was found to be sterile. Using a set of CAP59
primers, Lucas et al. (2010) only found a serotype D allele and sug-
gested that the serotype A allele was lost. Since CBS132 was
selected as holotype of C. neoformans variety neoformans (=sero-
type D) after recognition of C. neoformans variety grubii (=serotype
A) with type strain H99 (=CBS8710 = CBS10515) by Franzot et al.
(1999), the proper genetic characterization of this strain became
even more important. These authors, however, also stated that ser-
otype may not be a stable phenotypic character. Taken together
these data strongly suggest that CBS132, which most likely repre-
sent an authentic isolate made by Sanfelice, is a serotype AD hybrid
isolate. This, in our opinion, disqualiﬁes this strain as the type
strain of C. neoformans as it has genetic and phenotypic properties
of both serotype A and serotype D background. The hybrid nature
of CBS132 also makes it difﬁcult, if not impossible, to decide
whether C. neoformans as described by Sanfelice (1895) represents
serotype D [as it is seen by most contemporary researchers] or ser-
otype A? In our opinion it is best to interpret it simply as a serotype
AD hybrid that originated as a result from a cross between C. neo-
formans representing serotype A, and ‘C. deneoformans’ represent-
ing serotype D (see below for the new taxonomy).
Serotype A isolates are by far clinically more relevant, both in
number of patients and the typical meningitis it usually causes
(Park et al., 2009). Thus cryptococcal meningitis is mainly caused
by C. neoformans serotype A isolates, especially in HIV-infected
patients, and globally causes an estimated one million new infec-
tions with over 625,000 casualties each year (Park et al., 2009).
Thus at a global scale cryptococcosis is clearly connected to sero-
type A isolates, which, in our opinion, favors the naming of the spe-
cies representing serotype A isolates as C. neoformans. We realize
that this opposes the proposal made by Franzot et al. (1999) in
which varietal status was given to serotype A isolates as C. neofor-
mans variety grubii Franzot, Salkin & Casadevall. However, we
assume that the clinical ﬁeld will beneﬁt most from naming sero-
type A strains as C. neoformans as this clearly links the most com-
mon pathogen with the major disease it causes.
For selecting a new type strain of C. neoformans two options
seem preferable. The ﬁrst option is to select the putative original
isolate of Saccharomyces hominis, CBS879 (=ATCC4189) made by
Busse (1895) that is serotype A (Drouhet, 1997) and genotype
AFLP1/VNI (Boekhout et al., 2001). Moreover, based on the
sequence analysis presented here it belongs to the core cluster ofC. neoformans serotype A. Unfortunately, this strain has not been
studied widely. The second option is to select a strain that has been
widely studied. In this aspect we agree with Franzot et al. (1999)
who selected strain H99 (=CBS8710 = CBS10515) as holotype for
variety grubii (=serotype A isolates), because the strain is widely
used as an experimental model in many studies, and its genome
has been released recently (Janbon et al., 2014). Belay et al.
(1996) conﬁrmed the serotype A status of the isolate. We favor this
last option to keep H99 as epitype for C. neoformans.
If we discard CBS132 as a type strain, this also implicates that a
new type strain has to be selected to represent the species agreeing
with serotype D for which we propose the name C. deneoformans to
remind the close relationship with C. neoformans (See Taxonomy
below). Similarly as for H99, we consider that strain B3501
(=CBS6900) is a good representative for this genotypically and sero-
logically well characterized species. This isolate is genetically well
studied, it has been widely used as a model strain in many experi-
ments, it is serotype D (Belay et al., 1996) and the analysis of its gen-
ome has set the standard of the ﬁeld (Loftus et al., 2005). Thus we
propose to use CBS6900 as holotype for C. deneoformans (see
Taxonomy below] with ex-type strains CBS6900 = B3501.
In 2002, C. gattii (Vanbreuseghem & Takashio) Kwon-Chung &
Boekhout was proposed as a new species and conserved against C.
bacillisporus Kwon-Chung & J.E. Bennett and C. hondurianus
Castellani (Kwon-Chung et al., 2002). More than a century ago,
Curtis (1896) described Saccharomyces subcutaneous tumefaciens
that turned out to represent C. gattii (Drouhet, 1997). Serologically,
the original Curtis’ isolate CBS1622 (=ATCC2344) belongs to sero-
type B (Drouhet, 1997) and was found to belong to genotype
AFLP4/VGI (Boekhout et al., 2001; Hagen et al., 2012b).
Vanbreuseghem and Takashio (1970) described C. neoformans var.
gattii based on a specimen that was isolated from spinal ﬂuid of a
man in Kinshasa, Congo, now Democratic Republic of Congo
(Africa). In 1978 C. bacillisporus was described (Kwon-Chung et al.,
1978) and, consequently, when both species are considered to be
conspeciﬁc only one valid name could be used. Since the involve-
ment of C. gattii in a number of globally emerging outbreaks this
name has largely gained popularity and this was one of the argu-
ments to conserve the name C. gattii (Vanbreus. & Takashio)
Kwon-Chung & Boekhout over C. bacillisporus Kwon-Chung & J.E.
Bennett (Kwon-Chung et al., 2002). Presently, we propose to
describe all ﬁve major genotypic lineages present in the C. gattii
complex (Figs. 1 and 2) as species. The type strains of C. gattii
RV20186 (=CBS6289 = ATCC32269 = MUCL30449) belongs to geno-
typic group AFLP4/VGI, and has serotype B (Belay et al., 1996;
Boekhout et al., 1997, 2001), whereas that of C. bacillisporus
ATCC32608
(=CBS6955 = CBS6916 = DBVPG6225 = MUCL30454 = NIH191) afﬁl-
iates with genotypic group AFLP5/VGIII and has serotype C
(Boekhout et al., 1997, 2001). Thus, these two type strains represent
different species (see below), despite that theyweremating compe-
tent. Thus thenameC. bacillisporushas to beused for theAFLP5/VGIII
genotypic cluster. For the other three genotypic lineages in the C.
gattii species complex, namely the genotypic clusters AFLP6/VGII,
AFLP7/VGIV and AFLP10/VGIV, no older names are available and
new names will be proposed that retain ‘gattii’ in order to link them
to the C. gattii species complex (see below Taxonomy).
4.8. One fungus = One name nomenclature
In the 5th edition of the reference work ‘The Yeasts – A taxo-
nomic study’ (Kurtzman et al., 2011a) both C. neoformans and C.
gattii are treated under the teleomorphic genus Filobasidiella
(Kwon-Chung, 1976, 2011; Kwon-Chung et al., 1982). With the
current ‘One fungus = One name’ concept for naming fungal spe-
cies (Hawksworth et al., 2011) using two names for the same
32 F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–48species is no longer accepted. This renders the question whether to
use the asexual (i.e., Cryptococcus) or the sexual (i.e., Filobasidiella)
name? As the name Cryptococcus is also the denominator for the
disease cryptococcosis, and because it is much more widely used
we favor to use Cryptococcus above Filobasidiella. For instance, in
Google Scholar searching Filobasidiella resulted in 2680 hits,
Cryptococcus gave 115,000 hits and cryptococcosis 29,100 hits
(February 10th, 2015). The ‘Filobasidiella’ clade includes also F. lutea
and F. depauperata (Kwon-Chung, 2011) and these two species
have to be renamed under Cryptococcus if that genus name is to
be used for the clade. A further complication is that the genus
Cryptococcus as it is currently recognized is highly polyphyletic
with species distributed in all four orders of Tremellomycetes
(Fonseca et al., 2011; Millanes et al., 2011). The genus is in urgent
need for revision using monophyly as discerned by multigene or
comparative genomics analyses as the leading principle. Thus, if
the Filobasidiella lineage is considered to represent the genus
Cryptococcus, by far the majority of currently named cryptococcal
species need to be renamed. A phylogenetic analysis by using six
genes of most currently described yeast and yeast-like species in
Tremellomycetes is underway and this will provide a base for
reclassiﬁcation and renaming the currently named Cryptococcus
species in Tremellomycetes (Liu et al., 2015).
5. Taxonomy
5.1. Cryptococcus neoformans (Sanfelice) Vuillemin
In: Vuillemin, P., 1901, Les blastomycètes pathogens. Rev. Gen.
Sci. 12: 732–751.
Serotype A (Belay et al., 1996; Boekhout et al., 1997, 2001),
genotype AFLP1, AFLP1A, AFLP1B (Boekhout et al., 2001; Bovers
et al., 2008a), AFLP genotype VNB (Litvintseva et al., 2006), PCR ﬁn-
gerprint and URA5-RFLP molecular type VNI and VNII (Meyer et al.,
2009, 2011).
Mycobank: MB119294.
Epitype NYSD 1649, New York State Herbarium, Albany, New
York, U.S.A. Herbarium. Holotype of C. neoformans var. grubii.
Ex-type material also preserved as CBS H-21964. Ex-type cultures
CBS8710 = H99 = CBS10515.
Isolated by A. Proctor, Durham, North Carolina, U.S.A. from
patient with Hodgkins lymphoma.
Genotype AFLP1, serotype A, mating-type a (Bovers et al.,
2008a). Isolated from a patient with Hodgkins lymphoma, A.
Proctor > J. Perfect, Durham, North Carolina, U.S.A.
5.1.1. Conﬁrmed synonyms
Saccharomyces neoformans Sanfelice, 1894. In: Sanfelice, F.,
1894, Contributo alla morfologia e biologia dei blastomiceti
che si sviluppano nei succhidi alcuni frutti. Ann. Igien. 4: 463–
495. Authentic strain CBS132 [=serotype AD hybrid].
Debaryomyces neoformans (Sanfelice) Redaelli, Ciferri &
Giordano, 1937. In: Redaelli, P., Ciferri, R., Giordano, A., 1937,
Debaryomyces neoformans (Sanfelice) nobis n. comb. pour les
espèces du groupe Saccharomyces hominis-Cryptococcus
neoformans-Torula histolytica. Boll. Sez. Ital. Soc. Int. Microbiol.
9: 24–28.
Cryptococcus hominis Vuillemin, 1901. In: Vuillemin, P., 1901,
Les blastomycètes pathogens. Rev. Gen. Sci. 12: 732–751.
CBS879 = ATCC4189 is a possible authentic isolate of the strain
that was isolated by Busse (1895) and named C. hominis by
Vuillemin (1901). According to Lodder & Kreger-van Rij
(1952) strains from this species were received in 1924 from
Ota in Paris and from Voss in 1925, which makes the identity
of CBS879 questionable with respect to its authenticity.Saccharomyces hominis Constantin, 1901. Cited as a synonym
under Filobasidiella neoformans by Kwon-Chung (2011). As this
most likely also represent the species found by Busse the syn-
onymy under C. neoformans may be correct.
Atelosaccharomyces hominis (Vuillemin) Todd & Herrman, 1936.
In: Todd, R.L., Herrmann, W.W., 1936, The life cycle of the
organism causing yeast meningitis. J. Bact. 32: 89–97.
Torulopsis hominis (Vuillemin) Redaelli, 1931. In: Redaelli, P.,
1931, Il problema della Torulopsidaceaea e dei loro rapporti
con lúomo e con la patologia umana studiato particularmente
in Italia. (Blastomiceti e blstimicosi). Riv. Biol. 13: 171–235.
Candida psicrophylicus Niño, 1934. In: Speroni D, Llambías J,
Parodi SE, Niño FL. 1934, Blastomicosis humana generalizada
por criptococo (n. sp.). Estudio parasitológico, anátomopatoló
gico, clínico y experimental. Bol. B. Aires Univ. Nac. Inst. Clin.
Quir. 5:94–155. Authentic strain CBS996, genotype AFLP1, sero-
type A (Boekhout et al., 2001).
Cryptococcus neoformans (Sanfelice) Vuillemin variety grubii
Franzot, Salkin & Casadevall. In: Franzot et al., 1999,
Cryptococcus neoformans var. grubii: separate varietal status
for Cryptococcus neoformans serotype A isolates. J. Clin.
Microbiol. 37: 839. Holotype NYSD1649, New York State
Herbarium, Albany, New York, U.S.A. Ex-type cultures
H99 = CBS8710 = CBS10515, genotype AFLP1, serotype A
(Boekhout et al., 2001). Note that in Franzot et al. (1999)
Filobasidiella neoformans variety neoformans is listed as the
teleomorph for C. neoformans variety grubii. The holotype of this
species, BPI71853 is, however, based on a crossing between
NIH12 (=CBS6885)  NIH430 (=CBS6886) (Kwon-Chung,
1975), which both are serotype D strains (Boekhout et al.,
1997, 2001; Martinez et al., 2001). This incongruence between
the anamorphic and teleomorphic species concepts with
respect to serotype designation makes this anamorph-
teleomorph connection incorrect.
Note: In The Yeasts, a taxonomic study, 5th edition, many syn-
onyms are listed for Cryptococcus neoformans, the anamorph of
Filobasidiella neoformans (Kwon-Chung, 2011). For most of them
no material is available for study and thus the actual species des-
ignation could not be conﬁrmed. Consequently, these names have
to be rejected.
Description based on strains CBS996, CBS8710, CBS8336,
CBS10085 (=WM148), CBS10515, P152.
After 3 days at 25 C in 3% glucose medium, sediment is pre-
sent; yeast cells are globose, usually with a single bud, but occa-
sionally some cells may adhere, 4.0–7.0  4.0–7.0 lm. Bigger
cells measuring up to 9 lm diameter are present, On YMoA, streak
colonies are 5–6.5 mm width, smooth, moist to mucoid, shiny,
creamish white, with an entire margin; cells are subglobose to glo-
bose, 4.0–6.0 lm in diameter, usually with one bud, but occasion-
ally with two buds. On Dalmau plates only yeast cells are present.
On MEA colonies measure 8–11 mm, and are pale yellowish beige
(pale isabella), and becoming highly mucoid. The Filobasidiella
teleomorph has dikaryotic hyphae, clamp connections, and cylin-
drical clavate basidia with four chains of somewhat elongate,
slightly rough basidiospores (Litvintseva et al., 2003; Nielsen
et al., 2003, 2007; Velagapudi et al., 2009). Serotype A (Boekhout
et al., 1997, 2001; Dromer et al., 1993), genotype AFLP1
(Boekhout et al., 2001), PCR ﬁngerprint and URA5-RFLP molecular
type VNI (Meyer et al., 2009, 2011). Clades F–H in Fig. 1.
5.1.2. Occurrence and habitats
Cryptococcus neoformans was found to be the most commonly
occurring species comprising 63% [genotypes AFLP1/VNI,
AFLP1A/VNB/VNII and AFLP1B/VNII combined] of 2755 globally col-
lected isolates (Meyer et al., 2011). Among the clinically and
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among the environmental isolates somewhat lower with 42%
(Meyer et al., 2011). Over 52% of the isolates came from
HIV-infected patients and more than 16% from apparently
immunocompetent people (Meyer et al., 2011). C. neoformans has
a global occurrence (Mitchell et al., 2011) and is known from
Europe (e.g., Austria, Belgium, Bulgaria, Croatia, France, Germany,
Greece, Hungary, Italy, Netherlands, Poland, Portugal, Serbia,
Spain, Switzerland, UK, Russia); Asia (e.g., China, India, Indonesia,
Israel, Japan, Kuwait, Papua New Guinea, Philippines, Qatar,
Thailand); Oceania (e.g., Australia, New Zealand); Africa (e.g.,
Botswana, Congo, Rwanda, South Africa, Zimbabwe); North
America (Canada, U.S.A.); Central and South America (e.g.,
Argentina, Brazil, Colombia, Chile, Cuba, French Guiana,
Guatemala, Mexico, Peru, Venezuela) (Arsic Arsenijevic et al.,
2014; Cattana et al., 2013; Debourgogne et al., 2011; Escandón
et al., 2006; Guinea et al., 2010; Hagen et al., 2012a;
Illnait-Zaragozi et al., 2010; Khayhan et al., 2013; Meyer et al.,
2011; Mlinaric-Missoni et al., 2011; Pan et al., 2012; Viviani et al.,
2006). The percentage among environmentally obtained isolates
ranged from 14% (Oceania), 30% (North America), 40% (Europe) to
47% (South America) (Meyer et al., 2011).
The species is known from pigeons, other birds, trees and soils
(Mitchell et al., 2011). C. neoformans is widely isolated from drop-
pings from a variety of birds, especially the common pigeon
(Columba livia), but also from doves (e.g., spotted dove,
Melopsittacus unolatus; zebra dove, Geopelia striata), ducks
(white-faced whistling duck, Dendrocygna viduata), Indian peafowl
(Pavo cristatus), cockatoos and other psittacine birds (e.g., Cacatua
roseicapilla) (Filiú et al., 2002), passerine birds (e.g., canary,
Serinus canaria domestica), birds of prey (e.g., spotted eagle-owl,
Bubo africanus; buzzard, Buteo buteo; common kestrel, Falco tinnun-
culus; black kite,Milvus migrans), bird cages at a commercial aviary
(Cafarchia et al., 2006; Costa Sdo et al., 2009). The species is
reported to cause minimally subcutaneaous disease in pigeons
(Malik et al., 2003). Cryptococcus neoformans is also reported from
various mammals, such as dogs, cats, cows, bandicoot rats, striped
grass mouse, gorilla, as well as various veterinary samples (eye,
nose, blood, lung, kidney, ulcerated cheek, osteolytis, parasinal)
and a hippopotamous cage (Bauwens et al., 2004; Boekhout et al.,
2001; Danesi et al., 2014; Lugarini et al., 2008; Magalhães et al.,
2012; Malik et al., 2003; Morera et al., 2014; O’Brien et al., 2004;
Singer et al., 2014; Singh et al., 2007). Tree species from which C.
neoformans has been isolated belong to the following families:
Anacardiaceae (Mangifera indica), Annonaceae (Polyaltha longifolia),
Apocynaceae (Alstonia scholaris), Bignoniaceae (Tabebuia guayacan),
Chrysobalanaceae (Licania (Moquilea) tomentosa), Combretaceae
(Terminalia catappa, T. arjuna), Cupressaceae (Cupressus semper-
virens), Fabaceae (Acacia decurrens, A. nilotica, Anadenanthera pere-
grina, Butea monosperma, Caesalpinia peltophoroides, Cassia ﬁstula,
C. grande, Colophospermummopane, Dalbergia sissoo,Myroxylon per-
uiferum, Prosopis juliﬂora, Senna multijuga, S. siamea, Tamarindus
indica, Tipuana tipu), Fagaceae (Quercus macrantha), Lauraceae
(Laurus species), Malvaceae (Adansonia digitata, Theobroma cacao),
Meliaceae (Azadirachta indica), Moraceae (Ficus microcarpa, F. reli-
giosa, F. tequindamae), Myrtaceae (Eucalyptus camaldulensis, E.
deglupta, E. globosus, Syzygium cucumi), Palmae (Phoenix species),
Pinaceae (Cedrus deodara, Pinus species), Rosaceae (Prunus dulci),
Rubiaceae (Guettarda acreana), Rutaceae (Aegle marmelos),
Sapotaceae (Manilkara hexandra, Mimusops elengi). Note that
Fabaceae are represented with 15 species. Besides the species is
known from a cockroach, soil, desert soil, house dust, decaying
wood, debris, and pine needles (Boekhout et al., 2001; Chowdhary
et al., 2011, 2012b; Colom et al., 2012; Costa Sdo et al., 2009;
Grover et al., 2007; Illnait-Zaragozí et al., 2012; Mitchell et al.,
2011; Mischnik et al., 2014; Randhawa et al., 2006; Refojo et al.,2009). The species is able tomate at woody debris of Acacia mearnsii
and Eucalyptus camaldulensis (Botes et al., 2009).
5.1.3. Epidemiology
Cryptococcus neoformans has a worldwide occurrence and the
majority of clinical isolates, predominantly isolated from
HIV-infected or otherwise immunosuppressed individuals, belong
to this species (Arsic Arsenijevic et al., 2014; Bii et al., 2007;
Calvo et al., 2001; Chan et al., 2014; Cogliati, 2013; Dromer et al.,
1994; Favalessa et al., 2014a; Govender et al., 2011; Guinea
et al., 2010; Hagen et al., 2012a; Illnait-Zaragozí et al., 2010; Li
et al., 2012b; Liaw et al., 2010; Pan et al., 2012; Pfaller et al.,
1998; Poonwan et al., 1997; Sanchini et al., 2014; Souza et al.,
2010; Thompson III et al., 2009; Tsujisaki et al., 2013; Viviani
et al., 2006). Numerous globally initiated epidemiological studies
reported that, irrespective of the source of the included C. neofor-
mans isolates, they exclusively were of the mating-type a (Arsic
Arsenijevic et al., 2014; Bii et al., 2007; Casali et al., 2003; Chen
et al., 2008; Chowdhary et al., 2011; Escandón et al., 2006;
Hagen et al., 2012a; Hiremath et al., 2008; Feng et al., 2008b;
Guinea et al., 2010; Litvintseva et al., 2005; Lugarini et al., 2008;
Matsumoto et al., 2007; Mihara et al., 2013; Park et al., 2014b;
Romeo et al., 2012; Sanchini et al., 2014; Simwami et al., 2011;
Yan et al., 2002), with the exception of a few that reported
mating-type a isolates (Freire et al., 2012; Hsu et al., 1994;
Litvintseva et al., 2006; Viviani et al., 2006) (Supplementary
Table 4).
There are indications that infections with C. neoformans are
due to a genetic risk proﬁle among HIV-infected individuals
(Netea, 2013; Rohatgi et al., 2013) and that an altered immune
response enhance C. neoformans infection in mice (Leongson
et al., 2013). However, in South-East Asian cryptococcosis
patients the majority of isolates were observed to be
HIV-negative (Chau et al., 2010; Chen et al., 2008; Choi et al.,
2010; Pan et al., 2012), but also at other localities C. neoformans
infections among immunocompetent individuals have been
found (Hagen et al., 2012a; Liaw et al., 2010; Mlinaric-Missoni
et al., 2011). It has been observed that inhibitory Fc receptors,
FcyRIIB, may play a role in cryptococcal infection in such appar-
ently immunocompetent individuals (Hu et al., 2012).
5.1.4. Susceptibility to antifungals
Isolates are usually susceptible to the standard clinically used
antifungals, including amphotericin B, 5-ﬂuorocytosine, ﬂucona-
zole, itraconazole, posaconazole, voriconazole, and the novel anti-
fungal isavuconazole (Arsic Arsenijevic et al., 2014; Bii et al.,
2007; Calvo et al., 2001; Chowdhary et al., 2011; de Fernandes
et al., 2003; Guinea et al., 2010; Hagen et al., 2012a;
Illnait-Zaragozi et al., 2010; Kobayashi et al., 2005; Lee et al.,
2012; Li et al., 2012b; Liaw et al., 2010; Mlinaric-Missoni et al.,
2011; Morera-López et al., 2005; Pan et al., 2012; Pfaller et al.,
1998; Poonwan et al., 1997; Souza et al., 2010; Tewari et al.,
2012; Tsujisaki et al., 2013). Some isolates showed elevated MICs
or resistance to amphotericin B (Andrade-Silva et al., 2013; Lee
et al., 2012; Li et al., 2012b; Matos et al., 2012), 5-ﬂuorocytosine
(Arsic Arsenijevic et al., 2014; Bii et al., 2007; Calvo et al., 2001;
Chowdhary et al., 2011; Hagen et al., 2012a; Matos et al., 2012;
Pan et al., 2012), ﬂuconazole (Andrade-Silva et al., 2013; de
Fernandes et al., 2003; Hagen et al., 2012a; Lee et al., 2012;
Matos et al., 2012; Morera-López et al., 2005; Pan et al., 2012;
Sar et al., 2004; Tangwattanachuleeporn et al., 2013; Tewari
et al., 2012) and itraconazole (Bii et al., 2007). Resistance to ﬂu-
conazole has been described in 20 cases, but therapeutic failure
cannot be fully attributed to altered susceptibility (Cheong and
McCormack, 2013). Fluconazole resistant isolates were also
observed in India, Indonesia and Thailand as were ﬁve ﬂuconazole
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(Khayhan et al., 2013; Pan et al., 2012). Isolates of C. neoformans
genotype AFLP1/VNI were found to have a signiﬁcantly higher geo-
metric mean MIC for ﬂuconazole than isolates of the two subgeno-
types AFLP1A/VNB/VNII and AFLP1B/VNII (Chong et al., 2010). C.
neoformans has been observed to be more susceptible to several
antifungals when compared to C. gattii (genotype AFLP4/VGI)
(Chowdhary et al., 2011) and C. deuterogattii (genotype
AFLP6/VGII) (Trilles et al., 2012), but less susceptible for
5-ﬂuorocytosine and amphotericin B when compared to C. gattii
(Chau et al., 2010).
Epidemiological cutoff values (ECVs) were recently established,
with ECVs for amphotericin B 0.5 lg/ml for genotype AFLP1/VNI
and 1 lg/ml for non-genotyped C. neoformans isolates;
5-ﬂuorocytosine 8 lg/ml and 16 lg/ml for non-typed
C. neoformans isolates; ﬂuconazole 8 lg/ml and 16 lg/ml for
non-genotyped C. neoformans isolates; itraconazole 0.25 lg/ml and
0.5 lg/ml for non-genotyped C. neoformans isolates; posaconazole
and voriconazole 0.25 lg/ml C. neoformans and non-genotyped C.
neoformans isolates; and isavuconazole 0.06 lg/ml for
non-genotyped C. neoformans isolates and 0.12 lg/ml for genotype
AFLP1/VNI isolates (Espinel-Ingroff et al., 2012a,b, 2015).
5.1.5. Virulence
Isolates of C. neoformans showed the highest growth rate at
37 C compared to the other species (referred to as genotypes,
Thompson III et al., 2014). A difference in fungal burden has been
observed between male and female mice, with the former being
more prone to have a higher fungal burden (Carroll et al., 2008).
Furthermore, pathogenicity assays showed that macrophages from
human females phagocytise more C. neoformans cells than those
obtained from human males, but that those from the latter were
found to be faster killed by cryptococcal cells (McClelland et al.,
2013). On the contrary, by using the nematode Caenorhabditis ele-
gans it was observed that male nematodes were more resistant
against C. neoformans infection compared to hermaphrodite nema-
todes (Van den Berg et al., 2006). Virulence of C. neoformans (cited
as molecular type VNI, Thompson III et al., 2014) as assessed in a
Drosophila host was lower if compared to C. bacillisporus (cited as
molecular type VGIII). Similarly, growth rates at 30 C were also
lower of compared to C. bacillisporus, but at 37 C growth rates of
C. neoformans (cited as molecular type VNI) were highest.
Similarly at 30 C on L-DOPA medium the species produced more
melanin than C. gattii (cited as molecular type VGI), C. bacillisporus
(cited as molecular type VGIII), C. deuterogattii (cited as molecular
type VGII) and C. tetragattii (cited as molecular type VGIV). Capsule
size was less than that of all members of the C. gattii species com-
plex (Thompson III et al., 2014).
5.2. Cryptococcus deneoformans Hagen & Boekhout, sp. nov.
Etymology: ‘de’neoformans, indicating that it represents the
serotype D [‘de’] isolates of the C. neoformans species complex, as
well as to indicate that the species is not the proper C. neoformans,
with ‘de’ meaning ‘off’.
Mycobank: MB810281.
Holotype CBS H-21965. Ex-type cultures CBS6900 = CBS7697 =
B-3501 = DBVPG6228. Isolated by K.J. Kwon-Chung, Bethesda,
Maryland, U.S.A., from crossing.
Genotype AFLP2, serotype D, mating-type a (Boekhout et al.,
2001; Bovers et al., 2008a).
5.2.1. Conﬁrmed synonyms
Saccharomyces neoformans Sanfelice, 1894. In: Sanfelice, F.,
1894, Contributo alla morfologia e biologia dei blastomicetiche si sviluppano nei succhidi alcuni frutti. Ann. Igien. 4: 463–
495. Type CBS132 [=serotype AD hybrid].
Filobasidiella neoformans Kwon-Chung (1975). In: Kwon-Chung,
K.J., 1975, A new genus Filobasidiella, the perfect state of
Cryptococcus neoformans. Mycologia 67: 1197–1200. This teleo-
morph description was based on crossing NIH12
(=CBS6885)  NIH430 (=CBS6886) (Kwon-Chung, 1975), which
both are serotype D and belong to genotype AFLP2/VNIV
(Boekhout et al., 1997, 2001; Bovers et al., 2008a; Martinez
et al., 2001). The holotype BPI71843, a result from the above
indicated crossing, is deposited in the National Fungus
Collection, Beltsville, Maryland, U.S.A. (Kwon-Chung, 1975,
2011). Unfortunately, in later papers NIH433, and not NIH430,
was indicated to represent the type culture of F. neoformans
(Kwon-Chung, 1976). According to Martinez et al. (2001)
NIH433 is also a serotype D isolate. Kwon-Chung et al. (2011)
reported that in the 1975 paper in which F. neoformans was
described (Kwon-Chung, 1975) compatible crossing were
observed between mating-types a and a strains of serotype D,
as well as between serotype A and serotype D strains, but we
could not conﬁrm this when checking the original 1975
publication.
Filobasidiella neoformans variety neoformans Kwon-Chung,
1982. In: Kwon-Chung, K.J., Bennett, J.E. & Rhodes, J.C. 1982,
Taxonomic studies on Filobasidiella species and their ana-
morphs. Antonie van Leeuwenhoek 48: 25–38. This variety is
based on the same holotype as listed above.
Description based on strains CBS882, CBS918, CBS5728,
CBS6900, CBS10079 (=WM629), BD5.
After 3 days at 25 C in 3% glucose medium, sediment is pre-
sent; yeast cells are globose, subglobose, ellipsoid, to ovoid, 4.0–
7.0  4.0–6.5 lm, usually with a single bud, but occasionally some
cells may adhere. Occasionally yeast cells germinate with a short
cylindrical germ tube, 12–15  1.2–2.5 lm (i.e., CBS5728). On
YMoA, streak colonies are 5.0–6.0 mm width, smooth, moist to
mucoid, shiny, creamish white, with an entire margin; cells are
broadly ellipsoid, subglobose to globose, 3.5–7.0 lm in diameter,
On Dalmau plates only yeast cells present, but CBS5728 showed
short ﬁlaments. On MEA colonies measure approximately 8 mm
diameter, pale yellowish beige (pale isabella), highly mucoid. The
Filobasidiella neoformans teleomorph has dikaryotic hyphae, clamp
connections, cylindrical clavate basidia with four chains with
ovoid, ellipsoid, to globose basidiospores that are ﬁnely rough
(Fraser et al., 2003; Kwon-Chung, 1975; Nielsen et al., 2007;
Velagapudi et al., 2009). Serotype D (Belay et al., 1996; Boekhout
et al., 1997, 2001; Dromer et al., 1993), genotype AFLP2
(Boekhout et al., 2001), PCR ﬁngerprint and URA5-RFLP molecular
type VNIV (Meyer et al., 2009, 2011). Clade I in Fig. 1.
5.2.2. Occurrence and habitats
Based on extensive genotyping studies comprising 2755 isolates
this species belonged to 5% of the isolates [molecular type VNIV]
(Meyer et al., 2011). Among the clinically and veterinary isolates
(n = 1250) this was also 5% and among the environmental isolates
4% (Meyer et al., 2011). Only 1.6% of the isolates came from
HIV-infected patients and 0.2% from apparently immunocompetent
people (Meyer et al., 2011). In some European countries however,
the incidence of this species is higher, e.g., the Netherlands 12%
(Hagen et al., 2012a), Spain 20% (Guinea et al., 2010), Croatia 40%
(Mlinaric-Missoni et al., 2011), Serbia 29% (Arsic Arsenijevic et al.,
2014) and Italy 35% (Viviani et al., 2006). C. deneoformans is reported
to have a global occurrence with Europe as a more prevalent region
(Mitchell et al., 2011) and is known from Europe (e.g., Austria,
Belgium, Bulgaria, Czech Republic; Denmark, France, Germany,
Italy, Netherlands, Portugal, Spain, Switzerland, UK, Russia); Asia
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(Canada, U.S.A.); Central and South America (e.g., Brazil, Chile,
Colombia, Mexico, Peru) (Escandón et al., 2006; Guinea et al.,
2010; Hagen et al., 2012a; Medeiros Ribeiro et al., 2006; Meyer
et al., 2011; Viviani et al., 2006). The percentage of this species
was reported to range from 4% (Oceania, South America) to 19%
(Europe) among environmentally obtained isolates (Meyer et al.,
2011, but see above). The higher incidence in some parts of the
world, e.g., Europe, was explained by the higher temperature sensi-
tivity of this species if compared to C. gattii (Martinez et al., 2001).
The species is known from soil, pigeons and other birds, drop-
pings from pigeon (Columba livia), greyish eagle-owl (Bubo africa-
nus cinerascens), cuckoo and canary, as well as from cats and
dogs (Mitchell et al., 2011). C. deneoformans was isolated from a
nasal tumor of horse, a dead white mouse, milk from a mastitic
cow, and a mastitic cow (Boekhout et al., 2001). The species is also
reported from trees, but to a lesser extent than C. neoformans. Tree
species from which C. deneoformans has been isolated belonged to
the following families: Chrysobalanaceae (Licania (Moquilea)
tomentosa), Fagaceae (Quercus alba), and Myrtaceae (Eucalyptus
camaldulensis, E. tereticornis, Syzygium cucumi) (Boekhout et al.,
2001; Chowdhary et al., 2012b; Colom et al., 2012; Medeiros
Ribeiro et al., 2006; Mitchell et al., 2011).5.2.3. Epidemiology
Infections with C. deneoformans seems to be predominant
among patients that are immunocompromised, but the species is
also causing disease in apparently healthy individuals (Arsic
Arsenijevic et al., 2014; Hagen et al., 2012a; Guinea et al., 2010;
Mlinaric-Missoni et al., 2011; Sanchini et al., 2014). A correlation
between clinical background (patients are more often >60 years
of age, skin infections) has been described (Dromer et al., 1996).
Higher proportions of C. deneoformans infections have been
reported among patient cohorts from Europe (Cogliati, 2013;
Guinea et al., 2010; Sanchini et al., 2014; Viviani et al., 2006),
and smaller percentages from Asia (0.3%), Australia (1%), North
America (5%) and South America (1%) as reported in a large global
population review (Cogliati, 2013). Epidemiological studies
reported that the majority of the C. deneoformans isolates had the
mating-type a (Arsic Arsenijevic et al., 2014; Bii et al., 2007;
Casali et al., 2003; Hagen et al., 2012a; Litvintseva et al., 2005;
Sanchini et al., 2014; Viviani et al., 2006; Yan et al., 2002).
Although mating-type a C. deneoformans isolates are less com-
monly isolated, they are more common than mating-type a C. neo-
formans isolates, which are regarded as extremely rare (Arsic
Arsenijevic et al., 2014; Feng et al., 2008b; Hagen et al., 2012a;
Viviani et al., 2006) (Supplementary Table 4).5.2.4. Susceptibility to antifungals
Isolates are usually susceptible for the clinically used antifun-
gals amphotericin B, 5-ﬂuorocytosine, ﬂuconazole, itraconazole,
posaconazole, voriconazole and the novel compound isavucona-
zole (Arsic Arsenijevic et al., 2014; Guinea et al., 2010; Hagen
et al., 2012a; Mlinaric-Missoni et al., 2011; Thompson III et al.,
2009). Elevated MICs are reported for ﬂuconazole (Hagen et al.,
2012a), and a 5-ﬂuorocytosine resistant isolate has been described
(Kantarcioglu and Yücel, 2002). Epidemiological cutoff values
(ECVs) were recently established, with ECVs for amphotericin
being B 1 lg/ml for non-typed C. deneoformans isolates;
5-ﬂuorocytosine 16 lg/ml for non-typed C. deneoformans isolates;
ﬂuconazole 16 lg/ml for non-typed C. deneoformans isolates; itra-
conazole 0.5 lg/ml for non-typed C. deneoformans isolates;
posaconazole 0.25 lg/ml for non-typed C. deneoformans isolates;
voriconazole 0.12 lg/ml for C. deneoformans isolates; for isavu-
conazole no C. deneoformans speciﬁc ECV could be establishedand therefore the general ECV of 0.06 lg/ml is applied for this spe-
cies (Espinel-Ingroff et al., 2012a,b, 2015).
5.2.5. Virulence
Cryptococcus deneoformans is more often involved in soft-tissue
infections compared to C. neoformans (Sanchini et al., 2014). The
former species was found to be more susceptible to heat than
the latter and this may explain the higher incidence of C. deneofor-
mans in skin infections, as well as clearing of this species by fever
(Martinez et al., 2001).
5.3. Cryptococcus gattii (Vanbreuseghem & Takashio) Kwon-Chung
and Boekhout, 2002 (nomen conservandum, McNeil et al., 2006)
In: Kwon-Chung, K.J., Boekhout, T., Fell, J.W. & Diaz, M. 2002.
Proposal to conserve the name Cryptococcus gattii against C. hon-
durianus and C. bacillisporus (Basidiomycota, Hymenomycetes,
Tremellomycetideae). Taxon 51: 804–806.
Mycobank: MB372381.
Holotype: The dried holotype is not available anymore from the
Mycological Department, Institute of Tropical Medicine, Antwerp,
Belgium (Kwon-Chung, 2011).
Neotype: CBS H-21966. Ex-type cultures ATCC32269 =
CBS6289 = CBS8273 = IHEM11796 = MUCL30449 = NIH3233 =
RV20186.
Isolated by E. Gatti & R. Eeckels, June 1966, from spinal ﬂuid of
man, Democratic Republic of Congo.
Genotype AFLP4, serotype B, mating-type a (Boekhout et al.,
2001; Bovers et al., 2008a; Hagen et al., 2010a, 2012b), PCR ﬁnger-
printing and URA5-RFLP molecular type VGI (Meyer et al., 2009,
2011; Ngamskulrungroj et al., 2009).
5.3.1. Conﬁrmed synonyms
Saccharomyces subcutaneous tumefaciens Curtis, 1896. Authentic
strain CBS1622, genotype AFLP4, serotype B (Boekhout et al.,
2001). In: Curtis, F. 1896, Contribution à l’étude de la
Saccharomycose humaine. Ann. Inst. Pasteur 10: 449–468.
Invalid name, trinomium.
Cryptococcus hominis Vuillemin variety tumefaciens (Curtis)
Benham, 1935. Based on the same strain as S. subcutaneous
tumefaciens.
Cryptococcus hondurianus Castellani, 1933. Authentic strain
CBS883, genotype AFLP4, serotype B (Boekhout et al., 2001).
In: Castellani, A., 1933. Blastomycosis: a short general account.
Med. Press Circul. 136: 438–443. Although this name has prior-
ity over C. gattii a proposal to conserve the latter over C. hon-
durianus was accepted (McNeil et al., 2006), and the name C.
hondurianus is rejected.
Torulopsis hominis Vuillemin variety honduriana Castellani,
1933. In: Castellani, A., 1933, Observations on fungi isolated
from cases of blastomycosis cutis and blastomycosis pulmonalis
in North America and Europe. Remarks on blastomycetin. J.
Trop. Med. Hyg. 20: 297–321. Based on same authentic strain
as C. hondurianus.
Torulopsis neoformans variety sheppei Giordani, 1935. Authentic
strain CBS919, genotype AFLP4, serotype B (Boekhout et al.,
2001). In: Giordano, A., 1935, Rôle du Torulopsis neoformans
(Sanfelice) Red. En pathologie humaine. Boll. Sez. Ital. Soc.
Intern. Microbiol. 7: 119–123. [Invalid name, no latin diagnosis]
Cryptococcus neoformans variety gattii Vanbreuseghem and
Takashio, 1970. Type RV20186, genotype AFLP4, serotype B
(Boekhout et al., 2001). In: Vanbreuseghem, R. & Takashio, M.,
1970. An atypical strain of Cryptococcus neoformans (Sanfelice)
Vuillemin 1894. Part II. Cryptococcus neoformans var. gattii var.
nov. Ann. Soc. Belg. Méd. Trop. 50: 695–702.
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& Li, 1983 [nomen inval. no latin diagnosis]. Type CBS7229,
genotype AFLP4, serotype B (Boekhout et al., 2001). In: Liao,
W., Shao, J., Wu, S., Zhang, J. & Li, S., 1983. Cryptococcus neofor-
mans var. shanghaiensis caused meningitis. Chin. Med. J.
(English edt.) 96: 287–290.
Filobasidiella bacillispora and Filobasidiella neoformans var. bacil-
lispora Kwon-Chung, 1982 are listed as teleomorphs of
Cryptococcus gattii (Vanbreuseghem & Takashio) Kwon-Chung
& Boekhout (Kwon-Chung, 2011; Kwon-Chung et al., 2002),
but this teleomorph is not based on a crossing between C. gattii
strains, but between a strain of C. bacillisporus (CBS6955) and
one of C. deuterogattii (CBS6956, see below).
Description based on strains CBS6289, CBS7992 (=RV54130),
CBS10078 (=WM179), CBS10510 (=WM276), CBS11231 (=56A).
After 3 days at 25 C in 3% glucose medium, sediment is pre-
sent; cells are globose, subglobose, ellipsoid, fusoid to ovoid, 4.0–
7.0  3.5–6.0 lm, usually with a single bud, but occasionally some
cells may adhere. On YMoA, streak colonies are 5.0–6.0 mm width,
smooth, moist to mucoid, shiny, creamish white, with an entire
margin; cells are broadly ellipsoid, subglobose to globose, 4.0–
6.0 lm in diameter. On Dalmau plates only yeast cells present.
On MEA colonies measure approximately up to 8 mm, pale yellow-
ish beige (pale isabella), and are highly mucoid. Teleomorph
unknown, but most likely Filobasidiella-like. Genotype AFLP4
(Boekhout et al., 2001), serotype B (Belay et al., 1996; Boekhout
et al., 2001; Dromer et al., 1993; Hagen et al., 2010a, 2012b), PCR
ﬁngerprinting molecular type VGI (Meyer et al., 2009, 2011;
Ngamskulrungroj et al., 2009). Diagnosis: Clade D in Fig. 1.
5.3.2. Occurrence and ecology
Based on extensive genotyping studies of 2755 isolates C. gattii
(genotype AFLP4/VGI) comprised 9% of the isolates (Meyer et al.,
2011) with the same percentage among clinically and veterinary
isolates (n = 1250) (Meyer et al., 2011). Approximately 6% of the
clinical isolates came from apparent immunocompetent patients
and 0.4% from HIV-infected patients (Meyer et al., 2011). C. gattii
is reported as a globally occurring species with Australia being a
more prevalent region (Mitchell et al., 2011). Among the species
of the C. gattii complex, this species is most common in Europe,
Australasia and Asia (Chen et al., 2014). The species is known from
Europe (e.g., Austria, Belgium, France, Germany, Greece, Italy,
Netherlands, Portugal, Spain, Switzerland, UK); Asia (e.g., China,
India, Japan, Malaysia, Papua New Guinea/Southeast Asia,
Taiwan, Thailand, Vietnam); Oceania (e.g., Australia, New
Zealand); Africa (e.g., Congo, South Africa); North America
(Canada, U.S.A.); Central and South America (e.g., Argentina,
Brazil, Colombia, Cuba, Ecuador, Honduras, Mexico, Paraguay,
Peru, Venezuela) (Baró et al., 1998; Campbell et al., 2005;
Cattana et al., 2013; Chowdhary et al., 2012a,b; Colom et al.,
2012; Escandón et al., 2006; Illnait-Zaragozí et al., 2011; Lester
et al., 2011; Meyer et al., 2011). The percentage among environ-
mentally obtained isolates ranged from 1% (South America), 3%
(North America), 27% (Europe) to 70% (Oceania) (Meyer et al.,
2011). C. gattii is reported from trees belonging to various tree fam-
ilies: Annonaceae (Polyaltha longifolia), Combretaceae (Terminalia
catappa), Cupressaceae (Cupressus sempervirens), Fabaceae (Acacia
visca, A. nilotica, Cassia ﬁstula, Ceratonia siliqua, Tipuana tipu),
Meliaceae (Azadirachta indica), Myrtaceae (Eucalyptus camaldulen-
sis, E. citriodora, E. glomulifera, E. tereticornis, Eucalyptus spec.,
Syzygium cumini), Oleaceae (Olea spec.), Pinaceae (Cedrus deodara,
Pinus canariensis, P. halepensis, Pseudotsuga menziesii), Sapotaceae
(Manilkara hexandra, Mimusops elengi) and Ulmaceae (Ulmus cam-
pestris). The species is reported from bark hollows, detritus, woody
debris and soil near the base of trees (Chowdhary et al., 2012a;Mitchell et al., 2011; Refojo et al., 2009; Springer et al., 2014;
Vilcins et al., 2002).
The species is also reported from a variety of animals, such as
cats, cheetah, dogs, ferrets, goats (lung, brain, gut), a mastitic
cow, veterinary samples (Baró et al., 1998; Boekhout et al., 2001;
Campbell et al., 2005; Chowdhary et al., 2012b; Colom et al.,
2012; Illnait-Zaragozí et al., 2011; Kidd et al., 2004; Lockhart
et al., 2013; Mitchell et al., 2011; Morera et al., 2014; Singer
et al., 2014). Ferrets may be asymptomatic carriers (Colom et al.,
2012). In Australia, probably many more animal species, such as
psittacine birds and koala’s harbor this species. Probably a large
part of the reports by Australian workers, such as R. Malik and
M. Krockenberger, may relate to this species, but due to lack of
available genotyping studies this could not be conﬁrmed here.
5.3.3. Epidemiology
Although the majority of infections have been observed to cause
disease in apparently healthy individuals (Byrnes III et al., 2009;
Chau et al., 2010; McCulloh et al., 2011) it has also been isolated
from patients with underlying disease (Hagen et al., 2012b). C. gat-
tii cases have been reported in high numbers from Australia (39%),
while smaller percentages were found in Africa (1%), Asia (13.2%),
Europe (3.4%), North America (7%) and South America (4%)
(Cogliati, 2013). Large-scale epidemiological studies reported that
the percentage of mating-type a isolates can be up to 20–25% of
the globally collected C. gattii isolates (Fraser et al., 2005; Hagen
et al., 2012b). But studies from Australia and the U.S.A. reported
less than 7% of mating-type a isolates (Campbell et al., 2005;
Lockhart et al., 2013) or even mating-type a only as reported from
China (Chen et al., 2008; Feng et al., 2008b).
5.3.4. Susceptibility to antifungals
In general isolates of C. gattii are susceptible to amphotericin B,
5-ﬂuorocytosine, ﬂuconazole, itraconazole, posaconazole,
voriconazole and the novel compound isavuconazole, when deter-
mined according to the CLSI guidelines (Chowdhary et al., 2011;
Lockhart et al., 2012). C. gattii isolates were found to have the low-
est geometric mean MICs for ﬂuconazole compared to C. deutero-
gattii, which had the highest MIC values (Lockhart et al., 2012;
Silva et al., 2012; Trilles et al., 2012). This observation was also
seen for 5-ﬂuorocytosine, albaconazole and voriconazole (Trilles
et al., 2012). When compared to the formerly known C. neoformans
species complex comprising C. neoformans and C. deneoformans, the
MICs for 5-ﬂuorocytosine and amphotericin B were signiﬁcantly
lower for C. gattii. Epidemiological cutoff values (ECVs) have been
established for ﬂuconazole (8 lg/ml), itraconazole (0.5 lg/ml),
posaconazole (0.5 lg/ml) and voriconazole (0.12 lg/ml) (Lockhart
et al., 2012). Another, more extensive, study also assessed ECVs
as follows: amphotericin B 0.5 lg/ml, 5-ﬂuorocytosine 4 lg/ml,
ﬂuconazole 8 lg/ml, itraconazole, posaconazole and voriconazole
0.5 lg/ml, and isavuconazole 0.25 lg/ml (Espinel-Ingroff et al.,
2012a,b, 2015).
5.3.5. Virulence
By using a Galleria mellonella virulence model the virulence of C.
gattii, C. bacillisporus, C. deuterogattii and C. tetragattii was found to
be similar for all species, and all these species contained isolates
with more virulent phenotypes, as well as avirulent phenotypes
(Firacative et al., 2014). Virulence of C. gattii (cited as molecular
type VGI, Thompson III et al., 2014) as assessed in a Drosophila host
was lower if compared to C. bacillisporus (=molecular type VGIII).
Similarly, growth rates at 30 C were also lower when compared
to those of C. bacillisporus. Melanisation at 30 C using L-DOPA
medium was found less than that of C. neoformans (cited as molec-
ular type VNI, Thompson III et al., 2014). Capsule size was found to
be higher than those of C. deuterogattii and C. neoformans
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infection when infected with C. gattii if compared to C. deuterogattii
(O’Brien et al., 2004).
5.4. Cryptococcus bacillisporus Kwon-Chung & Bennett
In: Kwon-Chung, K.J., Bennett, J.E. & Theodore, T.S., 1978,
Cryptococcus bacillisporus sp. nov.: Serotype B-C of Cryptococcus
neoformans. Int. J. Syst. Bact. 28: 616–620.
Mycobank: MB312336.
Holotype: ATCC32608. Ex-type material also preserved as CBS
H-21967. Ex-type cultures ATCC32608 = CBS6955 = NIH191.
Isolated from spinal ﬂuid of patient with cryptococcal meningi-
tis, California, U.S.A.
Genotype AFLP5, serotype C, mating-type a (Boekhout et al.,
1997, 2001).
5.4.1. Conﬁrmed synonyms
Filobasidiella bacillispora Kwon-Chung pro parte, 1976. Type
BPI71855, National Fungus Collection, Beltsville, Maryland,
U.S.A., based on cross between NIH191 (=CBS6955 =
ATCC32608, genotype AFLP5, serotype C (Boekhout et al.,
1997, 2001)) and NIH444 (=ATCC32609 = CBS6956, genotype
AFLP6, serotype B (Boekhout et al., 1997, 2001; Kwon-Chung
et al., 1978). Thus this teleomorphic species is based on a cross-
ing between C. deuterogattii (CBS6956) and C. bacillisporus
(CBS6955). Therefore, we consider that the offspring of this
crossing represented a hybrid progeny.
Note: Cryptococcus bacillisporus Kwon-Chung & Bennett was
considered previously a synonym under C. gattii (Vanbreuseghem
& Takashio) Kwon-Chung & Boekhout with the latter name being
conserved and thus having priority (McNeil et al., 2006).
However, our current data show that they represent two species,
and, therefore, the name C. bacillisporus is reintroduced.
Description based on strains CBS8755, CBS6955, CBS10081
(=WM161 = WM175), WM728.
After 3 days at 25 C in 3% glucose medium a sediment is pre-
sent; cells are globose, subglobose, ellipsoid, to ovoid, usually with
a single bud, but occasionally some cells adhere, 4.0–7.0  3.7–
6.0 lm; bigger cells measuring 8–12  6.0–7.0 lm occur. On
YMoA, streak colonies are 4.0–5.0 mm width, smooth, moist to
somewhat mucoid, shiny, creamish white, with an entire margin;
cells are broadly ellipsoid, subglobose to globose, 3.5–7.5 lm in
diameter. Dalmau plates show only yeast cells. On MEA colonies
measure approximately up to 8 mm, pale yellowish beige (pale isa-
bella), highly mucoid; cells more ellipsoid to ovoid, 5.0–9.0  3.5–
7.0 lm, with polar and sympodial budding. Teleomorph with
Filobasidiella-state with ellipsoid smooth basidiospores (Byrnes III
et al., 2011; Fraser et al., 2003; Springer et al., 2014; Velagapudi
et al., 2009). Serotype C (Dromer et al., 1993; Boekhout et al.,
1997, 2001), genotype AFLP5 (Boekhout et al., 2001; Hagen et al.,
2010a, 2012b), PCR ﬁngerprinting and URA5-RFLP molecular type
VGIII (Meyer et al., 2009, 2011; Ngamskulrungroj et al., 2009);
MLST VGIIIa and VGIIIb (Springer et al., 2014). Clade C in Fig. 1.
5.4.2. Occurrence and ecology
Cryptococcus bacillisporus comprised 4% of 2755 globally col-
lected cryptococcal isolates (Meyer et al., 2011). Among clinically
and veterinary isolates (n = 1250) this was 3% and among environ-
mental isolates 6% (Meyer et al., 2011). Approximately, 2% from
1250 clinical isolates came from apparent immunocompetent
patients, and only 0.4% from HIV-infected individuals (Meyeret al., 2011). Among the species of the C. gattii species complex this
species comprised 11% (Chen et al., 2014). The species is known
from Europe (Belgium); Asia (India, Papua New Guinea/Southeast
Asia, South Korea), Oceania (Australia, New Zealand), Africa
(Botswana, South Africa, Tanzania, Malawi), North America
(Canada, and California, U.S.A.); South and Central America
(Argentina, Brazil, Colombia, Guatemala, Mexico, Venezuela)
(Campbell et al., 2005; Chaturvedi et al., 2005; Chen et al., 2014;
Escandón et al., 2006, 2010; Lester et al., 2011; Litvintseva et al.,
2005, 2011; Meyer et al., 2011; Springer et al., 2014). The species
is reported from some tree families, either directly or from soil
near the base of the trees: Altingiaceae (Liquidambar excelsa, L.
styraciﬂua), Combretaceae (Terminalia catappa); Myrtaceae
(Eucalyptus spec., Corymbia ﬁcifolia, Metrosideros excelsa) and
Pinaceae (Pinus canariensis) (Boekhout et al., 2001; Chowdhary
et al., 2013; Escandón et al., 2010; Mitchell et al., 2011; Springer
et al., 2014). C. bacillisporus has also been isolated from cats and
a cow (Lockhart et al., 2013; Singer et al., 2014).
5.4.3. Epidemiology
Cryptococcus bacillisporus is frequently isolated from immuno-
compromised individuals, especially among HIV-infected patients
(Byrnes III et al., 2011; Chaturvedi et al., 2005; Souza et al.,
2010). Little is known about the global distribution (Chowdhary
et al., 2013), but a large-scale epidemiological literature review
reported only small numbers from the various continents ranging
from only 0.1% from Asia and Europe up to 3% for Australia and
4% for North and South America (Cogliati, 2013). The species has
been noted from HIV-infected individuals in Southern California
(Byrnes III et al., 2011; Chaturvedi et al., 2005; Springer et al.,
2014), where trees have been identiﬁed as environmental reser-
voir. C. bacillisporus has also been isolated from HIV-infected indi-
viduals in Malawi and Botswana (Litvintseva et al., 2005). Studies
that made use of MLST showed the existence of two major clades,
named genotypes VGIIIa and VGIIIb (Byrnes et al., 2011; Springer
et al., 2014). The study by Springer et al. (2014) revealed the exis-
tence of a distantly related isolate that was regarded as being
subgenotype VGIIIc, but subsequent re-analysis of the data showed
that the isolate clustered together with the reference strain for C.
decagattii (Springer et al., 2014; this study; Fig. 5, Supplementary
Data). When MLST data of C. bacillisporus isolates from other recent
studies was re-analyzed it appeared that a third subgenotype
exists (this study; Fig. 5, Supplementary Data). Two studies that
included globally collected C. bacillisporus isolates reported 13%
to less than 5% of mating-type a (Fraser et al., 2005; Hagen et al.,
2012b). Lockhart et al. (2013), Byrnes et al. (2011) and Escandón
et al. (2006) studied C. bacillisporus isolates from the U.S.A. and
Colombia and reported mating-type a to a ratios of approximately
1–9, 1–5 and 0–1, respectively.
5.4.4. Susceptibility to antifungals
Isolates of C. bacillisporus are usually susceptible to ampho-
tericin B, 5-ﬂuorocytosine, ﬂuconazole, itraconazole, posaconazole,
voriconazole and the novel compound isavuconazole, when deter-
mined according to the CLSI guidelines (Chowdhary et al., 2013;
Lockhart et al., 2012; Souza et al., 2010). MIC values for ﬂucona-
zole, itraconazole and voriconazole were found to be lower com-
pared to C. tetragattii and C. deuterogattii), but higher than those
of C. gattii isolates (cited as molecular types VGIV, VGII, and VGI,
respectively, Lockhart et al., 2012). Another study found that the
MICs for 5-ﬂuorocytosine and itraconazole were lower than those
of C. neoformans (Singer et al., 2014). Epidemiological cutoff values
(ECVs) have been established for ﬂuconazole (8 lg/ml), itracona-
zole (1 lg/ml), posaconazole (0.12 lg/ml) and voriconazole
(0.12 lg/ml) (Lockhart et al., 2012). ECVs assessed in another, more
extensive, study were amphotericin B 1 lg/ml for non-typed
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zole 8 lg/ml; itraconazole 0.5 lg/ml; posaconazole 0.5 lg/ml for
non-typed isolates; voriconazole and isavuconazole 0.25 lg/ml
for non-typed isolates (Espinel-Ingroff et al., 2012a,b, 2015).
5.4.5. Virulence
Among the C. gattii species complex, isolates of C. bacillisporus
grew the best at 30 C (Thompson III et al., 2014). Using a
Galleria mellonella virulence model no signiﬁcant differences in vir-
ulence were found among the four species of the C. gattii species
complex (Firacative et al., 2014). Virulence of C. bacillisporus (cited
as molecular type VGIII, Thompson III et al., 2014) as assessed in a
Drosophila host was highest if compared to C. neoformans (=molec-
ular type VNI), C. gattii (=molecular type VGI), C. deuterogattii (=-
molecular type VGII) and C. tetragattii (=molecular type VGIV pro
parte). Similarly, isolates of this species showed the highest growth
rate at 30 C. Melanisation at 30 C using L-DOPA medium was
found less than that of C. neoformans (cited as molecular type
VNI, Thompson III et al., 2014). Capsule size was found to be higher
than those of C. deuterogattii and C. neoformans (Thompson III et al.,
2014). Virulence in mice ranged from avirulent to moderately vir-
ulent and correlated well with moderate intracellular proliferation
rates in macrophages (Springer et al., 2014).
5.5. Cryptococcus deuterogattii Hagen & Boekhout, sp. nov.
Etymology: ‘Deutero’, Greek for second, referring to the molec-
ular type VGII under which this species is hitherto known; ‘gattii’
referring to the Cryptococcus gattii species complex to which this
species belonged to previously.
Mycobank: MB810282.
Holotype: CBS H-21968. Ex-type cultures CBS10514 =
CDC-R265 = A1M-R265 = WM02.32 = AMFC2607.
Isolated from bronchial wash of man, Duncan, Vancouver
Island, British Colombia, Canada.
Genotype AFLP6, serotype B, mating-type a (Bovers et al.,
2008a; Hagen et al., 2010a, 2012b; Kidd et al., 2004).
5.5.1. Conﬁrmed synonym
Filobasidiella bacillispora pro parte (see above under C.
bacillisporus).
Description based on strains CBS10090 (=AV55), CBS10082
(=WM178), CBS10514 (=CDC-R265 = A1M-R265), CBS10865
(=CDC-R272 = A1M-R272).
After 3 days at 25 C in 3% glucose medium, a sediment is
present; cells are globose, subglobose, ellipsoid, to ovoid, usually
with a single bud, but occasionally some cells adhere,
4.0–7.5(8.5)  3.8–6.8(7.8) lm. Bigger cells measuring
9.0–13.0  9.0–11.0 lm occur. On YMoA, streak colonies are
5.0–6.0 mm width, smooth, moist to mucoid, shiny, creamish
white, with an entire margin; cells are broadly ellipsoid, subglo-
bose to globose, 4.0–8.0 lm in diameter. Dalmau plates show only
yeast cells, with those at the outermost margin somewhat smaller.
On MEA colonies measure approximately up to 8 mm, pale yellow-
ish beige (pale isabella), highly mucoid. Teleomorph with
Filobasidiella-state (Kidd et al., 2004; Voelz et al., 2013). Mating
experiments using two highly fertile tester strains of C. bacillisporus
(NIH312, B-4546) revealed a Filobasidiella teleomorph with four
chains of ellipsoid basidiospores. True clamp connections seem to
be present (Ngamskulrungroj et al., 2008). This teleomorph is,
however, considered by the present authors to represent the result
of an interspecies crossing. Serotype B, genotype AFLP6 (Boekhout
et al., 2001; Hagen et al., 2010a, 2012b; Kidd et al., 2004), PCR ﬁn-
gerprinting and URA5-RFLP molecular type VGII (Kidd et al., 2004;Meyer et al., 2009, 2011; Ngamskulrungroj et al., 2009). Clade A in
Fig. 1.5.5.2. Occurrence and ecology
Cryptococcus deuterogattii is a major emerging pathogen that
infects primarily apparent immunocompetent humans and animals
and that is causing some major outbreaks, most notably those on
Vancouver Island and the neighboring mainland of British
Colombia, Canada and the Paciﬁc Northwest, U.S.A. (Kidd et al.,
2004; Byrnes III et al., 2011; Fraser et al., 2005; Hagen et al.,
2013). The species seems emerging in Mediterranean Europe
(Hagen et al., 2012b) and has been found to infect tourists that vis-
ited endemic regions (Georgi et al., 2009; Hagen et al., 2010b;
Lindberg et al., 2007). C. deuterogattii comprised 13% of 2755 glob-
ally collected isolates of the C. gattii/C. neoformans species complex
(Meyer et al., 2011). Among the clinically and veterinary isolates
(n = 1250) this was 7% but among the 604 environmental isolates
35% (Meyer et al., 2011). Eighteen percent of 1250 isolates came
from apparent immunocompetent patients (Meyer et al., 2011).
Almost half of the isolates (47%) of isolates of representatives of
the C. gattii species complex comprised this species (Chen et al.,
2014). The species C. deuterogattii is known from Europe (e.g.,
France, Germany, Greece, Netherlands, Spain); Asia (e.g., China,
India, Japan, Malaysia, Papua New Guinea/Southeast Asia, South
Korea, Thailand, Vietnam); Oceania (e.g., Australia (Northern
Territory, Southwest), New Zealand); Africa (e.g., Congo, Senegal,
South Africa); North America (Canada, U.S.A.); Central and South
America (e.g., Aruba, Argentina, Brazil, Colombia, Costa Rica,
French Guiana, Mexico, Puerto Rico, Uruguay, Venezuela)
(Campbell et al., 2005; Chen et al., 2014; Datta et al., 2009;
Escandón et al., 2006; Hagen et al., 2012b, 2013; Lester et al.,
2011; Meyer et al., 2011). The percentage among environmentally
obtained isolates ranged from 10% (Oceania), 36% (South America)
to 61% (North America) (Meyer et al., 2011). As indicated by these
latter authors, the high incidence reported for North America may
be related to the ongoing outbreaks that stimulated environmental
sampling. The species has also been reported in a number of
patients from restricted geographic regions, such as Greece, Rio
de Janeiro and Para districts in Brazil, and Japan (Hagen et al.,
2012b; Okamoto et al., 2010; Pinto Junior et al., 2010). The species
has been reported from a number of plant families: Aceraceae (Acer
spec.), Betulaceae (Alnus rubra, Alnus spec.), Cupressaceae
(Cupressus lusitanica, Thuja plicata), Ericaceae (Arbutus menziesii),
Fabacaea (Acacia decurrens, Cassia grande, Senna siamea), Fagaceae
(Quercus garryana), Euphorbiaceae (Croton bogotanus, C. funck-
ianus), Lauraceae (Laurus spec.), Leguminosae (Caesalpinia coriaria),
Myrtaceae (Eucalyptus camaldulensis, E. tetradonta), Moraceae (Ficus
microcarpa, F. soatensis), Pinaceae (Cedrus spec., Picea spec., Pinus
radiata, Pinus spec., Pseudostuga menziesii), Rosaceae (Licania
(Moquilea) tomentosa, Prunus emargata, P. dulcis) and Rubiaceae
(Guattarda acreanus). The species is isolated from air, and from bark
and hollows, as well as ﬂowers of Eucalyptus camaldulensis
(Boekhout et al., 2001; Chowdhary et al., 2012b; Fortes et al.,
2001; Hagen et al., 2013; Kidd et al., 2004; Mitchell et al., 2011).
Also many animals have been found to be colonized or infected
by C. deuterogattii, such as alpaca and other camelids, cat, dog,
Dall’s porpoises, elk, ferret, goat, horse, llama, parrot, sheep, koalas,
Spinner dolphin (Hawaii) and veterinary samples. Veterinary
sources included tracheal wash, liver, and sinuses. The yeast
was also found in the nest of a communal wasp, Polybia occiden-
tialis, in Uruguay (Boekhout et al., 2001; Campbell et al., 2005;
Cardoso et al., 2013; Duncan et al., 2011; Hagen et al., 2013,
2014; Kidd et al., 2004; Kluger et al., 2006; Lockhart et al., 2013;
MacDougall et al., 2007; McGill et al., 2009; Mitchell et al., 2011;
Morera et al., 2014; Singer et al., 2014; Springer et al., 2014).
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Cryptococcus deuterogattii is predominantly found in
HIV-negative individuals (Chan et al., 2014; Favalessa et al.,
2014b; Hagen et al., 2012b; Kidd et al., 2004; Smith et al., 2014;
Soares et al., 2008) as well as in apparently immunocompetent ani-
mals (Cardoso et al., 2013; Duncan et al., 2005; Lester et al., 2004).
However, numerous cases of HIV-positive patients with a C.
deuterogattii infection have been described as well (Pinto Junior
et al., 2010; Poonwan et al., 1997). The species can cause disease
among children, especially in the South American Amazonean
regions (Debourgogne et al., 2012; Pinto Junior et al., 2010;
Santos et al., 2008; Soares et al., 2008). C. deuterogattii is frequently
reported from Australia (22%), North America (44.2%), South
America (17%), and to a lesser extent from Africa (0.25%), Asia
(1.7%) and Europe (0.3%), as reported in a large literature review
(Cogliati, 2013). A large proportion of the infections reported relate
to ongoing outbreaks in North America that have affected the
health of hundreds of humans and many more animals (Hagen
et al., 2013; Kidd et al., 2004), as well as from other smaller out-
breaks (Hagen et al., 2013; Raso et al., 2004). A large proportion
of the known mating-type a C. deuterogattii isolates was reported
from the South American continent, here the mating-type a iso-
lates were nearly outnumbered as over 95% of 119 investigated
Colombian C. deuterogattii isolates were found to be mating-type
a (Escandón et al., 2006). Another study reported a nearly equal
distribution of South American mating-type a and a isolates
(Hagen et al., 2013). Several studies that included numerous C.
deuterogattii isolates from the outbreaks at the North American
continent have reported that all these isolates were of the a
mating-type (Fraser et al., 2005; Hagen et al., 2013; Kidd et al.,
2004; Lockhart et al., 2013). Studies that investigated Australian,
European and North American reported that the majority of the
isolates were mating-type a, ranging from 0% to 12% of
mating-type a isolates (Byrnes et al., 2010; Campbell et al., 2005;
Carriconde et al., 2011; Hagen et al., 2012b).5.5.4. Susceptibility to antifungals
Isolates of C. deuterogattii are usually susceptible to the clinically
relevant antifungal compounds amphotericin B, 5-ﬂuorocytosine,
ﬂuconazole, itraconazole, posaconazole and voriconazole (Cardoso
et al., 2013; Datta et al., 2013; Favalessa et al., 2014a,b; Lockhart
et al., 2012; Poonwanet al., 1997; Tsujisaki et al., 2013).MICs are sig-
niﬁcantly higherwhen compared to other species of the C. gattii spe-
cies complex (Datta et al., 2013; Iqbal et al., 2010; Lockhart et al.,
2012; Silva et al., 2012), but the MIC for isavuconazole is low
(Datta et al., 2013). The geometric mean of the MIC for ﬂuconazole
is higher than that of C. gattii (Chong et al., 2010; Iqbal et al., 2010;
Lockhart et al., 2012; Silva et al., 2012). This was also true for
5-ﬂuorocytosine (Chong et al., 2010; Trilles et al., 2012), and alba-
conazole and voriconazole (Trilles et al., 2012). Interestingly, signif-
icant differences exist between the three subgenotypes of C.
deuterogattii (Iqbal et al., 2010). Isolates of C. deuterogattii were
found tobe less susceptible to the tested antifungal compounds than
of the C. neoformans species complex (Trilles et al., 2012). Resistance
to ﬂuconazole has been reported (Matos et al., 2012).
Epidemiological cutoff values (ECVs) have been established for ﬂu-
conazole (32 lg/ml), itraconazole (1 lg/ml), posaconazole (1 lg/ml)
andvoriconazole (0.5 lg/ml) (Lockhart et al., 2012). In another,more
extensive, study ECVs were assessed as follows: amphotericin B
0.5 lg/ml for genotype AFLP6A/VGIIa and 1 lg/ml for non-typed C.
deuterogattii isolates; 5-ﬂuorocytosine 16 lg/ml for non-typed C.
deuterogattii isolates; ﬂuconazole 8 lg/ml for genotype
AFLP6A/VGIIa and 32 lg/ml for non-typed C. deuterogattii isolates;
itraconazole 0.5 lg/ml; posaconazole 0.5 lg/ml; and voriconazole
and isavuconazole 0.25 lg/ml for genotype AFLP6A/VGIIa andnon-typed C. deuterogattii isolates (Espinel-Ingroff et al., 2012a,b,
2015).
5.5.5. Virulence
Cryptococcus deuterogattii seems to have a preference to cause
pulmonary disease and may be associated with certain
immunecompromising or otherwise predisposing host factors
(Chen et al., 2014; Harris et al., 2011; MacDougall et al., 2007,
2011). By using a Galleria mellonella model, virulence did not differ
signiﬁcantly between all species of the C. gattii species complex.
Isolates of all species can be either highly virulent or avirulent
(Firacative et al., 2014). Experiments showed that mice with an
AIDS-like disease are less susceptible to infection with C. deutero-
gattii infection than to C. neoformans (Leongson et al., 2013).
Virulence of isolates of C. deuterogattii (cited as molecular type
VGII) as assessed in a Drosophila host was found to be less than that
of C. bacillisporus as was the growth rate at 30 C (cited as molecu-
lar type VGIII, Thompson III et al., 2014). Melanisation at 30 C
using L-DOPA medium was found less than that of C. neoformans
(cited as molecular type VNI, Thompson III et al., 2014).
Virulence as observed in mice ranged from avirulent (environmen-
tal isolates) to highly virulent and generally correlated well with
intracellular proliferation values in macrophages. However, occa-
sionally nonconcordant results were seen in mice and macrophage
experiments (Hagen et al., 2013; Ma et al., 2009). Australian cats
showedmore extensive infection when infected with C. deuterogat-
tii if compared to C. gattii (O’Brien et al., 2004).
5.6. Cryptococcus tetragattii Hagen & Boekhout, sp. nov.
Etymology: ‘Tetra’, Greek for four, referring to the molecular
type VGIV under which this species was known previously; ‘gattii’
referring to C. gattii to which this species belonged previously.
Mycobank: MB810283.
Holotype: CBS H-21969. Ex-type cultures CBS10101 = WM779.
Isolated by V. Davis, 1994, from cheetah, South Africa.
Genotype AFLP7, serotype C, mating-type a (Bovers et al.,
2008a; Hagen et al., 2010a, 2012b).
Description based on strains CBS10101 (=WM779), B5742,
B5748, M27055.
After 3 days at 25 C in 3% glucose medium, a sediment is pre-
sent; cells are subglobose to globose, usually with a single bud,
but occasionally some cells may adhere, 4.0–7.5  4.0–7.0 lm.
On YMoA, streak colonies are 5.0–7.0 mm width, smooth, moist
to mucoid, shiny, creamish white, with an entire margin; cells
are broadly ellipsoid, subglobose to globose, 4.0–5.5 lm in diame-
ter. Dalmau plates show only yeast cells. On MEA colonies measure
approximately 9.0–11.0 mm width, pale yellowish beige (pale isa-
bella), highly mucoid. Teleomorph unknown, but most likely
Filobasidiella. Serotype C, genotype AFLP7 (Bovers et al., 2008a,
2009; Hagen et al., 2010a, 2012b), PCR-ﬁngerprinting and
URA5-RFLP molecular type VGIV, although not distinguishable
from C. decagattii (=genotype AFLP10) by this method (Hagen
et al., 2012b; Linares et al., 2015; Meyer et al., 2009, 2011;
Ngamskulrungroj et al., 2009). Clade E in Fig. 1.
5.6.1. Occurrence and ecology
The notion that C. tetragattii is in part identical to molecular
type VGIV (see above) makes it difﬁcult, if not impossible, to trans-
late information on occurrence and clinical incidence as reported
for molecular type VGIV to C. tetragattii and C. decagattii, respec-
tively. It is fair to state, however, that both species are relatively
rare. The incidence of molecular type VGIV strains among 2755 iso-
lates of the C. gattii/C. neoformans species complex was only 1%
(Meyer et al., 2011). The majority of isolates of the C. gattii species
complex in Africa seems to belong to this species (Chen et al.,
40 F. Hagen et al. / Fungal Genetics and Biology 78 (2015) 16–482014). The species is known from Africa (South Africa, Tanzania),
Asia (India), Europe (Spain, Sweden), Central America (Mexico,
Puerto Rico), and South America (Argentina, Colombia,
Venezuela) (Cogliati, 2013; Cogliati et al., 2012; Hagen et al.,
2010a, 2012b; Lester et al., 2011; Linares et al., 2015; Litvintseva
et al., 2005; Loperena-Alvarez et al., 2010; Springer and
Chaturvedi, 2010). The species [cited as molecular type VGIV] is
reported to originate from trees (Mitchell et al., 2011).
5.6.2. Epidemiology
Cryptococcus tetragattii seems rather rare as indicated by the
low number of isolates described so far (Cogliati et al., 2012;
Hagen et al., 2010a, 2012b; Linares et al., 2015; Litvintseva et al.,
2005; Loperena-Alvarez et al., 2010). Mating-type a C. tetragattii
isolates outnumber those that were mating-type a (Hagen et al.,
2012b), but other studies reported only mating-type a isolates
from Botswana, Malawi and India (Cogliati et al., 2012; Fraser
et al., 2005; Litvintseva et al., 2005).
5.6.3. Susceptibility to antifungals
Isolates of C. tetragattii are usually susceptible to the clinically rel-
evant antifungals amphotericin B, 5-ﬂuorocytosine, ﬂuconazole, itra-
conazole, posaconazole and voriconazole (Lockhart et al., 2012).
Isolates of the species were found to have higher geometric mean
MICs for ﬂuconazole, itraconazole and voriconazole when compared
to C. gattii andC. bacillisporus, but lowerwhen compared to C. deutero-
gattii (citedwith therespectivegenotypicdesignations, Lockhart et al.,
2012). Epidemiological cutoff values (ECVs) have been established for
ﬂuconazole (16 lg/ml), itraconazole (1 lg/ml), posaconazole
(1 lg/ml) and voriconazole (0.25 lg/ml) (Lockhart et al., 2012).
Another study also assessed ECVs as follows: amphotericin B 1 lg/ml
for non-typed C. tetragattii isolates; 5-ﬂuorocytosine 4 lg/ml for
non-typed C. tetragattii isolates; ﬂuconazole 16 lg/ml; itraconazole
1 lg/ml; posaconazole 0.5 lg/ml for non-typed C. tetragattii isolates;
andvoriconazoleand isavuconazole0.25 lg/ml fornon-typedC. tetra-
gattii isolates (Espinel-Ingroff et al., 2012a,b, 2015).
5.6.4. Virulence
By using a Galleria mellonella virulence model it was shown that
virulence of C. gattii, C. bacillisporus, C. deuterogattii and C. tetragattii
didnot differ signiﬁcantly, and in all specieshighly virulent and avir-
ulent phenotypes are known (Firacative et al., 2014). Virulence of
molecular type VGIV strains that represent C. tetragattii, namely
CBS10101, B5742 and B5748, as assessed in a Drosophila host was
found to be less than that of C. bacillisporus as was the growth rate
at 30 C (cited as molecular type VGIII, Thompson III et al., 2014).
Melanisation at 30 C using L-DOPA medium was found less than
that of C. neoformans (cited as molecular type VNI, Thompson III
et al., 2014).
5.7. Cryptococcus decagattii Hagen & Boekhout, sp. nov.
Etymology: ‘Deca’ from the Greek word for 10, referring to the
AFLP genotype number AFLP10 under which this species was hith-
erto known; ‘gattii’ from C. gattii, the species complex where the
species belonged to.
Mycobank: MB810284.
Holotype: CBS H-21970. Ex-type cultures CBS11687 =
IHEM14941S = IHEM14941 = RV 63979.
Isolated by J. Torres-Rodriguez (Barcelona, Spain) from a
HIV-positive man originating from Mexico in 1987.
Genotype AFLP10, serotype B, mating-type a (Hagen et al.,
2010a, 2012b).
Description based on strains CBS11687 (=IHEM14941S =
IHEM14941), IHEM14941W.After 3 days at 25 C in 3% glucose medium a sediment is pre-
sent; cells are broad ellipsoid, ovoid, subglobose to globose, usually
with a single bud, but occasionally some cells adhere, 4.0–
7.5  3.5–6.0 lm. Bigger cells measuring up to 10  8 lm occur.
On YMoA, streak colonies are 6.0–9.0 mm width, smooth, moist to
mucoid, shiny, creamish white, with an entire margin; cells are
broad ellipsoid to fusoid, subglobose to globose, 3.5–7.5(9.0) lm
in diameter. Dalmau plates show only yeast cells. On MEA colonies
measure 10–15 mm, pale yellowish beige (pale isabella), highly
mucoid. Teleomorph unknown, but most likely Filobasidiella-like.
Serotype B, genotype AFLP10 (Bovers et al., 2008a, 2009; Hagen
et al., 2010a, 2012b), PCR ﬁngerprinting molecular type VGIV,
although not distinguishable from AFLP7 by this method (Hagen
et al., 2012b; Meyer et al., 2009, 2011; Ngamskulrungroj et al.,
2009); MLST VGIIIc (Springer et al., 2014); Clade B with CBS11687
in Fig. 1. AFLP genotyping, multi-locus sequence typing (Meyer
et al., 2009) and MALDI-TOF MS separate C. decagattii from the clo-
sely related siblings C. bacillisporus (genotype AFLP5/VGIII) and C.
tetragattii (genotype AFLP7/VGIV) (Hagen et al., 2012a; Linares
et al., 2015; Trilles et al., 2014).
Data of isolates with a URA5-RFLP determined molecular type
VGIV that fell into a putative genotype AFLP5/VGIII cluster based
on MLST (marked as VGIII⁄ by Trilles et al., 2014) was re-analyzed
together with the two available C. decagattii isolates (Hagen et al.,
2012b). This revealed that one of these previously published MLST
genotype VGIII⁄ isolates was closely related to C. decagattii (Fig. 5).
Interestingly, this isolate WM1802 (=LA390; mating-type a, sero-
type B)was cultured froma clinical source that had aMexican origin
(Ngamskulrungroj et al., 2009; Trilles et al., 2014). A recent MLST
study on molecular type VGIII isolates from Southern California
(U.S.A.) showed that one isolate formed a long basal branch (named
molecular typeVGIIIcby theauthors) to a tighter clusterwithmolec-
ular typeVGIIIa andVGIIIb isolates (Springeret al., 2014). Thebranch
lengthpresented in the studybySpringer et al. (2014) support, in our
opinion, the taxonomic status of the clinical isolates 7685027 and
IHEM14941 (=CBS11687) as a distinct species. The MLST data from
the atypical molecular type VGIIIc clinical isolate 7685027
(mating-type a) were re-analyzed as described above for the other
molecular type VGIII⁄ isolates, and this revealed that this isolate
was closely related to the two available C. decagattii isolates, as well
as to isolateWM1802 (Fig. 5; Supplementary Data). Clade B in Fig. 1.5.7.1. Occurrence and ecology
Cryptococcus decagattii is a rare species, currently ﬁve isolates
are known: CBS11687 (=IHEM14941S = IHEM14941) and
IHEM14941W (both Hagen et al., 2012b), 7685027 (Springer
et al., 2014), WM1802 (=LA390) and WM11.135 (both Trilles
et al., 2014). As indicated under C. tetragattii this species cannot
be distinguished from that species by conventional
PCR-ﬁngerprinting and URA5-RFLP. Hence it is impossible to
directly interpret most data on the distribution and clinical occur-
rence using strain designations based on PCR ﬁngerprinting.5.7.2. Epidemiology
Cryptococcus decagattii was originally reported from a
HIV-infected individual that originated from Mexico (Hagen et al.,
2010a, 2012b). The epidemiology of this species is not clear as the
species cannot be separated from C. tetragattii when URA5-RFLP is
applied (Hagen et al., 2010a, 2012b; Trilles et al., 2014).
Re-analysis of published MLST-data revealed the existence of two
other C. decagattii isolates, namely mating-type a isolate 7685027
(Springer et al., 2014) and mating-type aWM1802 (=LA390; Trilles
et al., 2014) (Fig. 5), the mating-type a to a ratio is 3:1 (this study;
Hagen et al., 2012b).
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Isolates of C. decagattii are susceptible to the antifungals
amphotericin B, 5-ﬂuorocytosine, ﬂuconazole, itraconazole,
posaconazole, voriconazole and isavuconazole (Hagen et al.,
2010a). Epidemiological cutoff values (ECV) could not be deter-
mined for C. decagattii, and, therefore general ECVs are used as fol-
lows: amphotericin B 1 lg/ml; 5-ﬂuorocytosine 4 lg/ml;
ﬂuconazole 16 lg/ml; itraconazole 1 lg/ml; posaconazole
0.5 lg/ml; and voriconazole and isavuconazole 0.25 lg/ml
(Espinel-Ingroff et al., 2012a,b, 2015).
5.7.4. Virulence
No data have been reported using vertebrate hosts. As indicated
above a Galleria mellonella virulence model did not show signiﬁ-
cant differences between the species of the C. gattii complex
(Firacative et al., 2014).
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